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!+,-$.,//)*# $%&&'()* LV D VXFFXOHQW SHUHQQLDO SODQW WKDW EHORQJV WR WKH IDPLO\ RI
&UDVVXODFHDHDQGLVRULJLQDOO\IURP0DGDJDVFDU!"#$%&&'()*LVZLGHVSUHDGLQWURSLFDODUHDV
ZRUOGZLGHDQGKDVEHHQXVHG LQ WUDGLWLRQDOPHGLFLQH ,Q(XURSH5XGROI6WHLQHU LQWURGXFHG
!"#$%&&'()*LQDQWKURSRVRSKLFDOPHGLFLQHIRUWKHILUVWWLPHLQ1RZDGD\V!"#$%&&'()*
LVDSK\WRWKHUDSHXWLFWKDWLVDYDLODEOHLQWKHIRUPRIOHDISUHVVMXLFHDQGOHDIH[WUDFWV%HVLGHV
RWKHU SRWHQWLDO LQGLFDWLRQV !"# $%&&'()* LV XVHG DQG H[DPLQHG IRU WKH WUHDWPHQW RI
K\SHUDFWLYHFRQGLWLRQV6LQFH!"#$%&&'()*KDVEHHQXVHGVXFFHVVIXOO\DVD WRFRO\WLF
DJHQWLQYDULRXVKRVSLWDOV7KHHIILFDF\FRXOGEHFRQILUPHGE\VHYHUDOHPSLULFDODVZHOODVE\
FOLQLFDO VWXGLHV 0&# 1%(+-# H[SHULPHQWV GHPRQVWUDWHG D UHOD[DQW HIIHFW RI WKH DTXHRXV OHDI
H[WUDFW OHDI SUHVV MXLFH DQG WKH IODYRQRLG IUDFWLRQ RI!"# $%&&'()* RQ VSRQWDQRXV KXPDQ
P\RPHWULDO FRQWUDFWLRQV $Q DGGLWLRQDO H[SHULPHQW DOVR VKRZHG D UHOD[DQW HIIHFW RI WKH
DTXHRXVOHDIH[WUDFWRQR[\WRFLQLQGXFHGFRQWUDFWLRQV

%DVHG RQ WKH IDFW WKDW !"# $%&&'()* KDV D UHOD[DQW HIIHFW RQ XWHULQH VPRRWK PXVFOH WKH
LQKLELWRU\ HIIHFW RQ XULQDU\ EODGGHU VPRRWK PXVFOH ZDV LQYHVWLJDWHG 2YHUDFWLYH EODGGHU
2$%LVDV\PSWRPDWLFV\QGURPHZKLFKDIIHFWVPDQ\LQGLYLGXDOVDQGLVGHILQHGDVXULQDU\
XUJHQF\ ZLWK RU ZLWKRXW XUJH LQFRQWLQHQFH XVXDOO\ ZLWK IUHTXHQF\ DQG QRFWXULD
$QWLPXVFDULQLFGUXJVDUHWKHILUVWOLQHSKDUPDFRWKHUDS\SUHVFULEHGWR2$%SDWLHQWV'XHWR
DQWLFKROLQHUJLF VLGH HIIHFWV DQG LQVXIILFLHQW WKHUDSHXWLF HIIHFWV DQ DOWHUQDWLYH
SK\WRSKDUPDFHXWLFDOWUHDWPHQWLVLQFUHDVLQJO\GHVLUHG5HFHQWO\DUDQGRPLVHGGRXEOHEOLQG
SODFHERFRQWUROOHG VWXG\ GHPRQVWUDWHG D SRVLWLYH LPSDFW RI !"#$%&&'()*#  FKHZDEOH
WDEOHWV DJDLQVW SODFHER E\ UHGXFLQJ WKH PLFWXULWLRQ IUHTXHQF\ RYHU  KRXUV ,Q LQLWLDO




)RU WKH DGPLQLVWUDWLRQ RI D SK\WRWKHUDSHXWLF LW LV HVVHQWLDO WR KDYH H[WHQVLYH NQRZOHGJH
DERXW WKH FRQVWLWXHQWV DQG WKHLU WKHUDSHXWLF HIIHFWV DQG WR[LFLW\ 7KLV WKHVLV GHVFULEHV WKH
LVRODWLRQ DQG LGHQWLILFDWLRQ RI !"# $%&&'()* FRQVWLWXHQWV LQ D PHWKDQROLF OHDI H[WUDFW 7ZR
SKHQROLFDFLGGHULYDWLYHVDQGQLQHNQRZQ IODYRQRLGJO\FRVLGHVZHUH LVRODWHG LQFOXGLQJ WZR
QHZ QDWXUDO SURGXFWV EHORQJLQJ WR WKH IODYRQRLGV QDPHO\ TXHUFHWLQ 22Į/
DUDELQRS\UDQRV\OoĮ/UKDPQRS\UDQRVLGH22ȕ'JOXFRS\UDQRVLGHDQGP\ULFHWLQ
22Į/DUDELQRS\UDQRV\O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Į/UKDPQRS\UDQRVLGH%XIDGLHQROLGHVDVXEVWDQFHJURXS
ZLWK VHGDWLYH SRVLWLYH LQRWURSLF DQG &16UHODWHG DFWLYLWLHV LV NQRZQ LQ RWKHU!+,-$.,//)*
VSHFLHV HJ !"# 3'%4+5*-&(%'&)* DQG KDV EHHQ GHWHFWHG LQ WKH PHWKDQROLF H[WUDFW RI
!"#$%&&'()*#RQO\LQWUDFHDPRXQWV)RUWKLVUHDVRQIRXUUHIHUHQFHVXEVWDQFHVZHUHLVRODWHG

IURP !"# 3'%4+5*-&(%'&)* DQG VXEVHTXHQWO\ EHUVDOGHJHQLQDFHWDWH EU\RSK\OOLQ $
EHUVDOGHJHQLQDFHWDWH DQG EHUVDOGHJHQLQRUWKRDFHWDWH ZHUH GHWHFWHG LQ
!"#$%&&'()*#
%DVHGRQWKHVHILQGLQJVWKHPHWKDQROLFOHDIH[WUDFWRI!"#$%&&'()*KDVEHHQIUDFWLRQDWHGLQ
D IODYRQRLG EXIDGLHQROLGH DQG SRODU IUDFWLRQ 7KH HIIHFW RI WKHVH WKUHH IUDFWLRQV RQ
HOHFWULFDOO\ VWLPXODWHG SRUFLQH GHWUXVRU FRQWUDFWLRQV ZDV HYDOXDWHG DQG FRPSDUHG ZLWK
R[\EXW\QLQ 7KH IODYRQRLG IUDFWLRQ GHPRQVWUDWHG D GRVH DQG WLPHGHSHQGHQW LQKLELWLRQ RI
GHWUXVRUPXVFOHFRQWUDFWLOLW\DQGDVLJQLILFDQWPD[LPXPLQKLELWLRQRIXVLQJDPJP/
FRQFHQWUDWLRQ 7KH LQKLELWRU\ HIIHFW RI WKH IODYRQRLG IUDFWLRQ ZDV FRPSDUDEOH ZLWK WKH
PD[LPXP LQKLELWLRQ SURGXFHG E\ WKH UHIHUHQFH VXEVWDQFH R[\EXW\QLQ  0 DW 
%ODGGHUVWULSV WUHDWHGZLWK WKHEXIDGLHQROLGH IUDFWLRQ  ȝJP/GLGQRWSURGXFHDQ\
LQKLELWRU\ HIIHFW RQ GHWUXVRU FRQWUDFWLOLW\ 7KH SRODU IUDFWLRQ GHPRQVWUDWHG DQ XQH[SHFWHG
GRVHGHSHQGHQWLQKLELWLRQ+RZHYHUWKHREVHUYHGHIIHFWPD\EHH[SODLQHGE\GHFUHDVHGS+
FDXVHG E\ /PDOLF DFLG SUHVHQW LQ WKLV IUDFWLRQ 7KHVH UHVXOWV VXJJHVW WKDW IODYRQRLGV DUH
LPSRUWDQWIRUWKHLQKLELWLRQRIGHWUXVRUFRQWUDFWLOLW\
7R H[DPLQH WKH HIIHFW RI !"# $%&&'()* RQ KXPDQ GHWUXVRU PXVFOHV KXPDQ EODGGHU ZDOO
VDPSOHV ZHUH REWDLQHG IURP SDWLHQWV DIWHU UDGLFDO F\VWHFWRP\ 7KH %&# 1%(+- H[SHULPHQWDO
UHVXOWV FRQILUPHG WKH REVHUYHG LQKLELWRU\ HIIHFW RI WKH OHDI SUHVV MXLFH DQG WKH IODYRQRLG







!+,-$.,//)*# $%&&'()* LVW HLQH PHKUMlKULJH VXNNXOHQWH 3IODQ]H GLH ]XU )DPLOLH GHU
'LFNEODWWJHZlFKVH &UDVVXODFHDH JHK|UW XQG XUVSUQJOLFK DXV 0DGDJDVNDU VWDPPW
+HXW]XWDJHLVW%"#$%&&'()*LQQDKH]XDOOHQWURSLVFKHQ*HELHWHQGHU:HOW]XILQGHQXQGZLUG
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GXUFK5XGROI6WHLQHU LQGLHDQWKURSRVRSKLVFKH0HGL]LQHLQJHIKUW+HXWH LVW!"#$%&&'()* LQ
)RUP GHV %ODWWSUHVVVDIWHV RGHU GHU %ODWWDXV]JH HLQ 3K\WRWKHUDSHXWLNXP GDV QHEHQ
DQGHUHQ SRWHQWLHOOHQ ,QGLNDWLRQHQ ]XU %HKDQGOXQJ YRQ K\SHUDNWLYHQ =XVWlQGHQ HLQJHVHW]W
ZLUGE]ZXQWHUVXFKWLVW6HLWZLUG!"#$%&&'()*#LQYHUVFKLHGHQHQ.OLQLNHQHUIROJUHLFKDOV
7RNRO\WLNXP EHL YRU]HLWLJHU :HKHQWlWLJNHLW YHUDEUHLFKW 'LH :LUNVDPNHLW NRQQWH GXUFK
PHKUHUHHPSLULVFKHDEHUDXFKNOLQLVFKH6WXGLHQEHVWlWLJWZHUGHQ ,Q %&#1%(+-([SHULPHQWHQ
]HLJWHQ GHU ZlVVULJH %ODWWH[WUDNW GHU %ODWWSUHVVVDIW VRZLH HLQH )ODYRQRLG)UDNWLRQ DXV
!"#$%&&'()*# %OlWWHUQ HLQH 5HOD[DWLRQ GHU VSRQWDQHQ .RQWUDNWLRQHQ GHV KXPDQHQ
0\RPHWULXPV ,Q HLQHP ZHLWHUHQ ([SHULPHQW NRQQWH HLQH UHOD[LHUHQGH :LUNXQJ GHV
ZlVVULJHQ%ODWWH[WUDNWHVDXI2[\WRFLQLQGX]LHUWH.RQWUDNWLRQHQJH]HLJWZHUGHQ

%DVLHUHQG DXI GHU 7DWVDFKH GDVV !"# $%&&'()*# HLQH UHOD[LHUHQGH :LUNXQJ DXI GLH JODWWH
0XVNXODWXU GHV 8WHUXV KDW ZXUGH GHU KHPPHQGH (IIHNW DXI GHQ JODWWHQ 0XVNHO GHU
+DUQEODVH XQWHUVXFKW 'LH K\SHUDNWLYH %ODVH 5HL]EODVH LVW LQ GHU %HY|ONHUXQJ ZHLW
YHUEUHLWHWXQGGHILQLHUWVLFKDOV LPSHUDWLYHU+DUQGUDQJPLWRGHURKQH'UDQJLQNRQWLQHQ]XQG
WULWW KlXILJ PLW 3ROODNLVXULH XQG 1\NWXULH DXI $OV (UVWWKHUDSLH ZHUGHQ GHQ 3DWLHQWHQ
DQWLPXVNDULQLVFKH 0HGLNDPHQWH YHUVFKULHEHQ DXIJUXQG DQWLFKROLQHUJH 1HEHQZLUNXQJHQ
VRZLH XQJHQJHQGHU :LUNXQJ VLQG DOWHUQDWLYH 7KHUDSLHP|JOLFKNHLWHQ ]% LP %HUHLFK GHU
3K\WRWKHUDSLH ]XQHKPHQG JHIUDJW .U]OLFK ]HLJWH HLQH UDQGRPLVLHUWH SODFHERNRQWUROOLHUWH
GRSSHOEOLQGH 6WXGLH HLQHQ SRVLWLYHQ 7UHQG YRQ!"# $%&&'()*#  .DXWDEOHWWHQ JHJHQEHU
3ODFHERLQ)RUPHLQHU$EQDKPHGHU0LNWLRQVIUHTXHQ]EHU6WXQGHQ(UVWH([SHULPHQWH
PLW !"# $%&&'()* 3UHVVVDIW    DP 6FKZHLQHGHWUXVRUPXVNHO %&# 1%(+- KDEHQ HLQH





3IODQ]H VRZLH GHUHQ:LUNXQJ XQG 7R[L]LWlW HVVHQWLHOO ,Q GHU YRUOLHJHQGHQ $UEHLW ZLUG GLH
,VROLHUXQJ XQG ,GHQWLIL]LHUXQJ YRQ 6XEVWDQ]HQ DXV GHP PHWKDQROLVFKHQ %ODWWH[WUDNW YRQ
!"#$%&&'()* EHVFKULHEHQ (V ZXUGHQ ]ZHL 3KHQROVlXUHGHULYDWH XQG YHUVFKLHGHQH EHUHLWV
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ZXUGH DXI GLH .RQWUDNWLOLWlW GHV HOHNWULVFK VWLPXOLHUWHQ 'HWUXVRUPXVNHOV JHJHQEHU
2[\EXW\QLQJHWHVWHW'LH)ODYRQRLG)UDNWLRQ]HLJWHHLQHGRVLVXQG]HLWDEKlQJLJH+HPPXQJ
GHU 'HWUXVRUNRQWUDNWLOLWlW EHL HLQHU .RQ]HQWUDWLRQ YRQ  PJPO ZXUGH GLH PD[LPDOH
+HPPXQJ YRQ  HUUHLFKW 'HU KHPPHQGH (IIHNW GHU )ODYRQRLG)UDNWLRQ DXI GLH
0XVNHONRQWUDNWLOLWlW ZDU YHUJOHLFKEDU PLW GHU PD[LPDOHQ +HPPXQJ GHU 5HIHUHQ]VXEVWDQ]
2[\EXW\QLQ  0 YRQ  'LH %XIDGLHQROLG)UDNWLRQ    ȝJPO ]HLJWH NHLQH






EHL 3DWLHQWHQ QDFK UDGLNDOHU =\VWHNWRPLH %ODVHQZDQGSUREHQ HQWQRPPHQ 'LH ELVKHULJHQ
5HVXOWDWHEHVWlWLJHQGHQKHPPHQGHQ(IIHNWGHV3UHVVVDIWHVXQGGHU)ODYRQRLG)UDNWLRQLP




XQG GHV6FKZHLQHGHWUXVRUPXVNHOV GXUFK!"# $%&&'()* VLQG lXVVHUVW YLHOYHUVSUHFKHQG XQG















7KH SK\WRWKHUDSHXWLF !+,-$.,//)*# $%&&'()* LV DSSURYHG E\ WKH 6ZLVV $JHQF\ IRU
7KHUDSHXWLF 3URGXFWV 6ZLVVPHGLF DV D PHGLFLQH ZLWKRXW DQ\ LQGLFDWLRQ 3K\VLFLDQV
SUHVFULEH!"#$%&&'()*SUHSDUDWLRQVIRUDZLGHVSHFWUXPRIGLDJQRVLVDQGVRPHWKHUDSHXWLF
HIIHFWV RI !"# $%&&'()* DUH FRQILUPHG E\ HPSLULFDO DQG FOLQLFDO VWXGLHV +RZHYHU OLWWOH LV
NQRZQDERXWWKHPHFKDQLVPRIDFWLRQ

,QD ILUVW VWHSZHKDG WRJDLQGHWDLOHGNQRZOHGJHDERXW WKHSK\WRFKHPLFDO FRPSRVLWLRQRI





EODGGHU V\QGURPH LV D K\SHUDFWLYH GLVRUGHU DQG DIIHFWV PDQ\ LQGLYLGXDOV 1RZDGD\V
DQWLPXVFDULQLFGUXJVDUHXVHGDV ILUVWOLQHSKDUPDFRWKHUDS\+RZHYHU WKH WUHDWPHQWRIWHQ
JRHVZLWKXQGHVLUDEOHDQWLFKROLQHUJLFVLGHHIIHFWV+HQFHORRNLQJIRUDOWHUQDWLYHWUHDWPHQWVLV
RQJRLQJWKHSK\WRWKHUDSHXWLF!"#$%&&'()*FRXOGEHRQHSRVVLELOLW\,QDVHFRQGSDUWRIWKLV
















2.1 Bryophyllum pinnatum 
2.1.1 Botanical systematics 
Bryophyllum pinnatum# $%&'&()*+# ,*-.# $/0.1# Kalanchoe pinnata# $%&'&()*+# 2-(/33.+4#
/0.3.0'5#Bryophyllum calycinum# $6&78/9:(0+# 9-73.;/# <3# <=-# >&'870#3>#?(&//:7&)-&-#&.@# 8/#
*.3A.#90#.:'-(3:/#B-(.&):7&(#.&'-/4#/:)=#&/#78>-#C7&.<4#&8(#C7&.<4# 73B-#C7&.<4#'8(&)7-#7-&>4#
)&<=-@(&7#9-77/4#&.@#D3-<=-#C7&.<1#B. pinnatum#8/#&#/:)):7-.<#C-(-..8&7#C7&.<#<=&<#8/#.&<8B-#<3#














@-)://&<-#&((&.;-@# 7-&B-/#&(-#/:)):7-.<#&.@# >7-/=0#@&(*#;(--.# $N8;1#J+1#K=-# 73A-(# 7-&B-/#
&(-# /)&773C-@# &.@# <(8''-@# 8.# (-@1# K=-# :CC-(# 7-&B-/# &(-# O# L# P# >378&<-1# K=-# 3B&<-L3973.;#
7-&B-/#&(-#&CC(3Q8'&<-70#!R#L#JR#)'#73.;#&.@#=&B-#.3<)=-/#9-&(8.;#&#@3('&.<#9:@1#S33<8.;#
B-;-<&<8B-# 9:@/# 3.# <=-# 7-&>#'&(;8.# &(-# B8/897-# &.@# &97-# <3# @-B-73C# 8.<3# &# =-&7<=0# C7&.<7-<#
A=-.#<=-#7-&>#>&77/#<3#<=-#;(3:.@#$N8;1#!+1#
G.#)3.<(&/<#<3#<=-#/-Q:&7#(-C(3@:)<83.#3>#'3/<#>73A-(8.;#C7&.</4#
B. pinnatum# =&/# &# (&<=-(# :.8T:-# '3@-# 3># B-;-<&<8B-#
(-C(3@:)<83.4#A=-(-90#03:.;#C7&.<7-</#@-B-73C#3.#<=-#-@;-/#3>#
7-&B-/# 9->3(-# 9-8.;# /=-@# >3(# C(3C&;&<83.1# U-/C8<-# <=-#
-.3('3:/#B-;-<&<8B-#>3()-#<=&<#8/#.--@-@#>3(#(-C(3@:)<83.4#<=-#
C7&.<# @-B-73C/# ;3(;-3:/# 8.>73(-/)-.)-/# >(3'# V3B-'9-(# <3#
E&()=4#&.@#>(:8</#8.#FC(87#WJX1#
K=-# C-.@:73:/# >73A-(/# &(-# )373:(-@# B837-<# 3.# <3C# <=-.# >&@-#








































































































































































































































7KH NQRZQ SK\WRFKHPLFDOV SUHVHQW LQ# !"# $%&&'()* LQFOXGH IODYRQRLGV DONDORLGV YDULRXV





IODYRQRLGV PDLQO\ TXHUFHWLQ DQG NDHPSIHURO JO\FRVLGHV KDYH EHHQ SUHYLRXVO\ LGHQWLILHG
6HYHUDO VWXGLHV KDYH UHYHDOHG WKH SUHVHQFH RI WKH IROORZLQJ IODYRQRLGV LQ !"# $%&&'()*#
)LJ
.DHPSIHURO  >@ NDSLQQDWRVLGH NDHPSIHURO 2Į/DUDELQRS\UDQRV\O o Į/
UKDPQRS\UDQRVLGH  >@ NDHPSIHURO 2ȕ'[\ORS\UDQRV\O o Į/
UKDPQRS\UDQRVLGH  >@ NDHPSIHULWULQ  NDHPSIHURO 22Į/
DFHW\OUKDPQRS\UDQRVLGH 2Į/UKDPQRS\UDQRVLGH  NDHPSIHURO 22Į/
DFHW\OUKDPQRS\UDQRVLGH 2Į/UKDPQRS\UDQRVLGH  NDHPSIHURO 22Į/
DFHW\OUKDPQRS\UDQRVLGH 2Į/UKDPQRS\UDQRVLGH  NDHPSIHURO 2Į'
JOXFRS\UDQRVLGH 2Į/UKDPQRS\UDQRVLGH  DI]HOLQ  ĮUKDPQRLVRURELQ  >@
NDHPSIHUROȕ'JOXFRS\UDQRVLGH >@DVWUDJDOLQTXHUFHWLQ >@TXHUFHWLQ
2Į/DUDELQRS\UDQRV\OoĮ/UKDPQRS\UDQRVLGHTXHUFLWULQTXHUFHWLQ22Į
/DUDELQRS\UDQRV\O o Į/UKDPQRS\UDQRVLGH 22ȕ'JOXFRS\UDQRVLGH  >@
TXHUFHWLQ GLDUDELQRVLGH >@ UXWLQ  >@ OXWHROLQ  >@ OXWHROLQ 2ȕ'JOXFRVLGH
>@P\ULFLWULQP\ULFHWLQ22Į/DUDELQRS\UDQRV\OoĮ/UKDPQRS\UDQRVLGH
 GLRVPLQH GLRVPHWLQ :Į/UKDPQRS\UDQRV\O o ȕ'JOXFRS\UDQRVLGH 
DFDFHWLQ 2Į/UKDPQRS\UDQRV\Oo ȕ'JOXFRS\UDQRVLGH  >@ ¶GLK\GUR[\
¶GLPHWKR[\IODYRQH2ȕ'JOXFRS\UDQRVLGH>@¶¶GLPHWKR[\TXHUFHWLQ>@
¶¶SHQWDK\GUR[\IODYRQH VWUXFWXUDO LQFRQVLVWHQFLHV >@ GLPHWKR[\¶




































































































































































































DQG NDODQWXERVLGH $ DQG % IURP!"# ();%</-+)* >@ ,Q WKHLU K\EULG!"# 3'%4+5*-&(%'&)* [
="#();%</-+)*6 DQRWKHU EXIDGLHQROLGH PHWK\O GDLJUHPRQDWH ZDV LGHQWLILHG >@ )XUWKHU




































































































































































































































































































































!"# $%&&'()* KDV EHHQ ZLGHO\ XVHG LQ WUDGLWLRQDO PHGLFLQH SDUWLFXODUO\ LQ KRW DQG PRLVW
UHJLRQV RI WKHZRUOGZKHUH WKH SODQWV JURZ VSRQWDQHRXVO\ VXFK DV0DGDJDVFDU 1LJHULD
7ULQLGDGDQG7REDJR ,QGLD ,QGRQHVLD3KLOLSSLQHV ,QGR&KLQDDQG%UD]LO7KH OHDYHVDQG
VWHPV DUH ELWWHU DQG GXH WR WKHLU DVWULQJHQW HIIHFWV WKH\ DUH HIIHFWLYH DJDLQVW GLDUUKRHD
IODWXOHQFH DQG YRPLWLQJ >@ &XUUHQWO\ WKH OHDYHV DUH XVHG WR WUHDW VHYHUDO GLVHDVHV DQG
DIIOLFWLRQV VXFK DV K\SHUWHQVLRQ NLGQH\ DQG XULQDU\ GLVRUGHUV >@ FRXJK RU WR SUHYHQW
DVWKPDV\PSWRPV>@,Q,QGLDWKHOHDYHVDUHXVHGDVDKHSDWRSURWHFWLYHPHGLFLQHWRWUHDW
MDXQGLFH>@)XUWKHUPRUHWKHOHDIH[WUDFWVRI!"#$%&&'()*KDYHDQWLXOFHU>@DQWLKLVWDPLQH




$QWKURSRVRSKLFDO PHGLFLQH $0 LV DQ LQWHJUDWLYH PXOWLPRGDO PHGLFDO V\VWHP WKDW ZDV
GHYHORSHG E\ WKH$XVWULDQ SKLORVRSKHU5XGROI 6WHLQHU  DQG WKH'XWFKPHGLFDO
GRFWRU,WD:HJPDQ$0LVFXUUHQWO\SUDFWLFHGLQFRXQWULHVZRUOGZLGH
,Q  WKH ILUVW DQWKURSRVRSKLFDO KRVSLWDO LQ $UOHVKHLP 6ZLW]HUODQG ZDV HVWDEOLVKHG E\
'U,WD:HJPDQ$0LVSUDFWLFHGE\SK\VLFLDQVWKDWDUHIXOO\WUDLQHGDQGTXDOLILHGLQXQLYHUVLW\
PHGLFLQH LQWHJUDWLQJ FRQYHQWLRQDO VNLOOV DQGPHWKRGVZLWK D KROLVWLF XQGHUVWDQGLQJ RIPDQ
DQG QDWXUH )URP WKLV SRLQW RI YLHZ WKH XQGHUVWDQGLQJ RI WKH KXPDQ EHLQJ LQ KLV HQWLUHW\
PHDQVWKHDFFHSWDQFHRIDWKUHHV\VWHPRUJDQLVDWLRQZLWKDSK\VLFDOERG\WKHVRXODQGWKH
VSLULW7KLVKROLVWLFYLHZRIWKHKXPDQEHLQJOHDGVWRDQXQGHUVWDQGLQJRIKHDOWKDQGLOOQHVV
WKDW GLIIHUV IURP FRQYHQWLRQDO PHGLFLQH DQG WR WUHDWPHQWV WKDW DUH VSHFLILFDOO\ DGDSWHG WR
HDFKLQGLYLGXDO
+RZGRHV$0GHVFULEHDQGLQWHUSUHW!"#$%&&'()*DQGLWVFKDUDFWHU"
!"# $%&&'()* KDV DQ H[FHSWLRQDO DELOLW\ WR OHW JURZ QHZ SODQWV IURP LWV OHDYHV'XH WR WKLV
SURFHVV ZH FDQ FRQVLGHU WKDW RQH OHDI FRQWDLQV WKH ZKROH SODQW DQG WKDW LW KDV D VWURQJ
YHJHWDWLYH IRUFHZLWK WKH WHQGHQF\ WRZDUG UHSURGXFWLRQ WKDWRFFXUV IURPRXWRI WKH OHDYHV










!"#$%&&'()* UHXQLWHV WKHVHWZRSDUWVRI WKHKXPDQRUJDQLVDWLRQWRUHVWRUHKROLVWLFEDODQFH
%DVHG RQ WKLV SULQFLSOH# !"#$%&&'()* KDV KLVWRULFDOO\ EHHQ XVHG WR WUHDW LQQHU UHVWOHVVQHVV
DQG DQ[LHW\ DQG WKHUHIRUH ZDV DOVR FDOOHG ³KHUEDO YDOLXP´ GXH WR LWV VHGDWLYH SURSHUWLHV
>@
,Q  !"# $%&&'()* SUHSDUDWLRQV ZHUH LQLWLDOO\ UHFRPPHQGHG E\ 5XGROI 6WHLQHU DV
DQWKURSRVRSKLFDOPHGLFLQHV WR WUHDWK\VWHULD >@+HGHVFULEHGK\VWHULDDV WKHFRQGLWLRQ LI
WKHZKROHVSLULWXDODQGHPRWLRQDOHQHUJ\LVVSHQWLQWRDQDFWLRQDQGWKHUHIRUHWKHERG\LVQRW
FDSDEOHDQ\PRUH WR UHJXODWHQRUPDOSK\VLFDO UHDFWLRQV >@ ,Q'U:HUQHU+DVVDXHU
LQWURGXFHG!"# $%&&'()* DV D WRFRO\WLF DJHQW WR SUHYHQW SUHPDWXUH ODERXU LQ $0 KRVSLWDOV
)URP DQ $0 YLHZSRLQW DQ LPEDODQFH LQ WKH DVWUDO DQG HWKHULF RUJDQLVDWLRQV FDQ OHDG WR
FUDPSV YDJLQDO LQIHFWLRQV DQG WKHUHIRUH WR SUHPDWXUH ODERXU 7KH KHDOWK\ LQWHUDFWLRQ RI
DVWUDO DQG HWKHULF ERGLHV LV VXSSRUWHG E\# !"# $%&&'()* 'U +DVVDXHU GHPRQVWUDWHG WKDW
WUHDWPHQW ZLWK!"# $%&&'()* FRXOG GHFUHDVH WKH GRVDJH RI EHWDPLPHWLFV RU HYHQ UHSODFH
WKHPDQGZDVDOVRZHOOWROHUDWHGLQZRPHQZLWKSUHPDWXUHODERXU>@







ZHUH UHFRUGHG LQ WKH (YD0HG GDWD EDQN DQG VKRZHG D EURDG LQGLFDWLRQ UDQJH >@
!"#$%&&'()*#SUHSDUDWLRQVDUHPDLQO\SURGXFHGE\:HOHGD$*ZKLOH:$/$+HLOPLWWHO*PE+
IRFXVHVRQWKHWD[RQRPLFDOO\UHODWHG!"#3'%4+5*-&(%'&)*




VXFKDVVOHHSGLVRUGHUV LQGXFHGE\ UHVWOHVVQHVVDQ[LHW\SDLQ LQGXFHGE\YLWDOZHDNQHVV
DQG UHFXUUHQW LQIODPPDWLRQ LQ WKHPHWDEROLF V\VWHP >@ &RPELQHG SUHSDUDWLRQV VXFK DV
!"#$%&&'()* 0HUFXULR FXOWXP RU $UJHQWR FXOWXP FRQWDLQ SODQWV ZHUH IHUWLOL]HG ZLWK WKH
FRUUHVSRQGLQJ KRPHRSDWKLF GLOXWHG PHWDO TXLFNVLOYHU RU VLOYHU 7KHVH SUHSDUDWLRQV DUH















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































$V GHVFULEHG SUHYLRXVO\# !"# $%&&'()* KDV EHHQ XVHG WR WUHDW YDULRXV GLVRUGHUV EDVHG RQ









$ UHWURVSHFWLYH VWXG\ LQFOXGLQJ  SUHJQDQW ZRPHQ LQYHVWLJDWHG WKH WRFRO\WLF HIIHFW RI
!"#$%&&'()* *URXS $ ZDV WUHDWHG ZLWK !"# $%&&'()*  LQIXVLRQ IROORZHG E\ WKH RUDO
WUHDWPHQW ZLWK WULWXUDWLR  7KH WUHDWPHQW LQ JURXS % VWDUWHG DOVR ZLWK!"#$%&&'()* 
LQIXVLRQDQGGXHWRDQLQDGHTXDWHHIIHFWDIWHUKRXUVZRPHQZHUHDGGLWLRQDOO\WUHDWHGZLWK
IHQRWHURO LQWUDYHQRXV LY RU SHU RV SR IROORZHG E\ WKH WUHDWPHQW ZLWK WULWXUDWLR 
!"#$%&&'()* VKRZHGD FRPSDUDEOHSRVLWLYHRXWFRPH WR IHQRWHURO DQGQR VLGHHIIHFWVZHUH
UHJLVWHUHG>@#
)URP  XQWLO  D WRWDO RI  GHOLYHULHV ZHUH GRFXPHQWHG DQG HYDOXDWHG E\ 'U
,VWYDQ9LOjJK\7KHVWXG\UHYHDOHGSUHJQDQWZRPHQZKRQHHGHGDWRFRO\WLFWKHUDS\DV
ZHOO DV  SUHPDWXUH GHOLYHULHV ZHUH UHJLVWHUHG ,Q WKH SHULRG IURP  WR 
IHQRWHURO ZDV XVHG WR SUHYHQW SUHPDWXUH ODERXU UHVXOWLQJ LQ DQ LQFLGHQFH RI SUHPDWXUH
GHOLYHULHV RI  ,Q WKH IROORZLQJ \HDUV KH LQWHJUDWHG !"# $%&&'()* LQ WKH WUHDWPHQW RI
SUHPDWXUH ODERXU )URP  WR  'U 9LOjJK\ WUHDWHG SUHJQDQW ZRPHQ DOPRVW
H[FOXVLYHO\ZLWK!"#$%&&'()*#GLOXWLR6LQFH!"#$%&&'()*ZDVXVHG IRU WKH WUHDWPHQWRI
SUHPDWXUHODERXUWKHLQFLGHQFHRISUHPDWXUHGHOLYHULHVGHFUHDVHGWR>@
,QDUHWURVSHFWLYHVWXG\WKHWROHUDELOLW\DQGWRFRO\WLFDFWLYLW\RILYDGPLQLVWHUHG!"#$%&&'()*
 FRPSDUHG ZLWK EHWDDJRQLVWV IHQRWHURO RU KH[RSUHQDOLQH ZHUH LQYHVWLJDWHG LQ 
SUHJQDQWZRPHQ7KLVVWXG\GHPRQVWUDWHGVLPLODUPDWHUQDODQGQHRQDWDORXWFRPHVLQERWK
WUHDWPHQW JURXSV +RZHYHU PDWHUQDO DGYHUVH HIIHFWV SDOSLWDWLRQ G\VSQRHD ZHUH
VLJQLILFDQWO\ UHGXFHG DQG WKH XVH RI FRUWLFRVWHURLGV DQG DQWLELRWLFVZDV ORZHU LQ WKH JURXS
WUHDWHG ZLWK !"# $%&&'()* 7KH QHRQDWDO RXWFRPHV DQG PRUELGLW\ UDWHV ZHUH VLPLODU RU

VXSHULRU LQ WKH !"# $%&&'()* WUHDWPHQW JURXS >@ ,Q DGGLWLRQ D SURVSHFWLYH UDQGRPLVHG
FOLQLFDOWUDLODVVHVVHGWKHHIILFDF\DQGVDIHW\RI!"#$%&&'()*#FKHZDEOHWDEOHWVYHUVXVD
FXUUHQWO\XVHGFDOFLXPDQWDJRQLVWQLIHGLSLQHIRUWKHWUHDWPHQWRISUHPDWXUHFRQWUDFWLRQV$
WRWDO RI  SUHJQDQW ZRPHQ ZHUH LQFOXGHG DQG VKRZHG QR FKDQJH LQ ELVKRS VFRUH IURP
YLVLW   K WR YLVLW  K 7KH WUHDWPHQW ZLWK !"# $%&&'()* DV ZHOO DV ZLWK QLIHGLSLQH
UHYHDOHGDVLJQLILFDQWGHFUHDVHLQWKHQXPEHURIFRQWUDFWLRQVKRIDQGUHVSHFWLYHO\
7KH QHRQDWDO RXWFRPH GLG QRW GLIIHU EHWZHHQ WKH WZR JURXSV +RZHYHU D VLJQLILFDQW
VKRUWHQLQJRIKRVSLWDOVWD\ZDVREVHUYHGZLWK!"#$%&&'()*>@
)XUWKHUPRUHWKHWRFRO\WLFDFWLYLW\RI!"#$%&&'()*REVHUYHGLQDQWKURSRVRSKLFDOPHGLFLQHZDV
FRQILUPHG LQ DQ %&# 1%(+- VWXG\ FRPSDUHG ZLWK IHQRWHURO!"# $%&&'()*# DTXHRXV OHDI H[WUDFW
PJ/ GHPRQVWUDWHG D GRVHGHSHQGHQW LQKLELWLRQ RI VSRQWDQHRXV KXPDQP\RPHWULXP
FRQWUDFWLRQVDOWKRXJKWKHFRQWUDFWLRQIUHTXHQF\LQFUHDVHG7KHH[WUDFWDOVRGHPRQVWUDWHGD
UHOD[DQW HIIHFW RQ R[\WRFLQLQGXFHG FRQWUDFWLRQV )HQRWHURO GHFUHDVHG P\RPHWULDO
FRQWUDFWLRQV DQG IUHTXHQF\ >@ $GGLWLRQDOO\ WKH HIIHFWV RQ VSRQWDQHRXV FRQWUDFWLRQV LQ
P\RPHWULDO VWULSV E\ !"# $%&&'()* OHDI SUHVV MXLFH DQG WHQWDWLYHO\ LGHQWLILHG IODYRQRLG
EXIDGLHQROLGHDQGFLQQDPLFDFLGIUDFWLRQVZDVLQYHVWLJDWHG%&#1%(+-$IWHUILYHUHJXODUPXVFOH
FRQWUDFWLRQV ȝ/RI WKH OHDI SUHVV MXLFH XQGLOXWHG DQG WKH IUDFWLRQV 
XQGLOXWHGZDVDGGHG WR WKH RUJDQ EDWK FKDPEHU 7KHHIIHFW RQ WKH DUHDXQGHU WKH FXUYH




DQGFDXVHGD UDSLGDQG ODUJH LQFUHDVH LQ WKH IUHTXHQF\ WRDIWHU WKH ILUVWDSSOLFDWLRQ
7KHDPSOLWXGHZDVUHGXFHGWRDIWHUWKHVHFRQGDSSOLFDWLRQ7KHWZRRWKHUIUDFWLRQVGLG






FRQGLWLRQV WKHSUHVV MXLFHZDVDEOH WRVLJQLILFDQWO\ LQKLELW WKHR[\WRFLQLQGXFHG LQFUHDVHRI
>&D@L7KHUHIRUH WKHWRFRO\WLFHIIHFW LVDVVXPHGWREH LQGHSHQGHQWRIH[WUDFHOOXODUFDOFLXP
FRQFHQWUDWLRQ6HFRQGO\ WKHHIIHFWRI WKH OHDISUHVV MXLFHZDV LQYHVWLJDWHGXVLQJ6+6<<






,Q D SURVSHFWLYH UDQGRPLVHG GRXEOHEOLQG SODFHERFRQWUROOHG VWXG\  SRVWPHQRSDXVDO
ZRPHQ VXIIHULQJ IURP RYHUDFWLYH EODGGHU 2$% RU XUJHQF\GRPLQDQW PL[HG XULQDU\
LQFRQWLQHQFH 08, ZHUH WUHDWHG ZLWK!"# $%&&'()*  FKHZDEOH WDEOHWV RU SODFHER 7KH
ZRPHQ WRRN [ EOLQGHG FDSVXOHVGXULQJZHHNV ,Q D WRWDO RI ZHHNV WKH\KDG ILYH
YLVLWVDQGZHUHDVNWRILOORXWGD\EODGGHUGLDULHVDQGDQVZHUWZRTXHVWLRQQDLUHVWKH.LQJ¶V
+HDOWK 4XHVWLRQQDLUH .+4 DQG WKH ,QWHUQDWLRQDO &RQVXOWDWLRQ RQ ,QFRQWLQHQFH 0RGXODU
4XHVWLRQQDLUH IRU 2$% ,&,42$% $IWHU WUHDWPHQW D SRVLWLYH WUHQG IRU!"# $%&&'()* ZDV
REVHUYHG FRPSDUHG WR SODFHER 7KH SULPDU\ HQGSRLQW WKHPLFWXULWLRQ IUHTXHQF\K ZDV
UHGXFHG IURPEHIRUH WRDIWHU WKH WUHDWPHQW S 7KHTXDOLW\RI OLIH 4R/ZDV
FRPSDUDEOHLQWKH!"#$%&&'()*DQGSODFHERJURXS>@
7KH HIIHFW RI# !"# $%&&'()* OHDI SUHVV MXLFH RQ SRUFLQH GHWUXVRU PXVFOH FRQWUDFWLOLW\ ZDV
LQYHVWLJDWHG LQ DQ RUJDQ EDWK FKDPEHU YHUVXV R[\EXW\QLQ 7KH SUHVV MXLFH  LQ WKH
FKDPEHU VLJQLILFDQWO\ LQKLELWHG GHWUXVRU FRQWUDFWLOLW\ LQGXFHG E\ HOHFWULFDO ILHOG VWLPXODWLRQ
()6E\FRPSDUHGWRWKHFRQWURO,QDGGLWLRQWKHSUHVVMXLFHGHPRQVWUDWHGD
VLJQLILFDQW UHOD[DQW HIIHFW  RQ FDUEDFKROLQGXFHG FRQWUDFWLRQV 7KH OHDI SUHVV MXLFH
GHPRQVWUDWHGDJRRGDFWLYLW\DOWKRXJKR[\EXW\QLQVKRZHGDJUHDWHULQKLELWLRQDQGUHOD[DWLRQ
RIWKHGHWUXVRUPXVFOHGHWDLOHGLQIRUPDWLRQDUHSURYLGHGLQ&KDSWHU>@
$GGLWLRQDO %&#1%(+-H[SHULPHQWVKDYH LQYHVWLJDWHG WKHHIIHFWRI OHDISUHVV MXLFHDQGGLIIHUHQW
IUDFWLRQVRI!"#$%&&'()*RQHOHFWULFDOO\ LQGXFHGSRUFLQHGHWUXVRUFRQWUDFWLOLW\7KH LQKLELWRU\
HIIHFW RI WKH OHDI SUHVV MXLFH ZDV VXFFHVVIXOO\ FRQILUPHG 7KH IODYRQRLG IUDFWLRQ UHGXFHG
PXVFOH FRQWUDFWLOLW\ LQ D GRVH DQG WLPHGHSHQGHQW PDQQHU DQG SURGXFHG D VLJQLILFDQW
PD[LPXPLQKLELWLRQRIXVLQJDPJP/FRQFHQWUDWLRQ7KHEXIDGLHQROLGHIUDFWLRQKDG
QR LQKLELWRU\HIIHFWRQFRQWUDFWLOLW\DW WKH LQYHVWLJDWHGFRQFHQWUDWLRQVDQG WKHSRODU IUDFWLRQ
VKRZHGDQXQH[SHFWHGLQKLELWRU\HIIHFWKRZHYHUWKLVHIIHFWPD\EHH[SODLQHGE\GHFUHDVHG














7KH EHKDYLRXUDO QHXURSKDUPDFRORJ\ RI WKH !"# $%&&'()* DTXHRXV OHDI H[WUDFW ZDV
LQYHVWLJDWHG LQ PLFH 7KH UHVXOWV GHPRQVWUDWHG QHXURVHGDWLYH &16 GHSUHVVDQW DQG
DQ[LRO\WLF DFWLYLWLHV )XUWKHUPRUH D GRVHGHSHQGHQWPXVFOH UHOD[DQW HIIHFW RI WKH DTXHRXV
H[WUDFWZDVREVHUYHGZKLFKZDVFRPSDUDEOH WRGLD]HSDP'LD]HSDP LVDEHQ]RGLD]HSLQH
WKDW LQFUHDVHV WKH HIIHFW RI ȖDPLQREXW\ULF DFLG *$%$ E\ ELQGLQJ WR WKH*$%$$ UHFHSWRU
DQG ILQDOO\ UHVXOWV LQ D VHGDWLYH DQWLFRQYXOVDQW DQ[LRO\WLF DQG PXVFOH UHOD[DQW HIIHFW
7KHUHIRUH LW LV VXJJHVWHG WKDW !"# $%&&'()* PD\ KDYH *$%$HUJLF DFWLYLW\ >@ 6RPH RI
WKHVH QHXURSKDUPDFRORJLFDO HIIHFWV ZHUH WHVWHG LQ 6ZLVV PLFH DSSO\LQJ D PHWKDQROLF
IUDFWLRQ6SHFLILFDOO\WKH*$%$FRQWHQWLQWKHEUDLQZDVHVWLPDWHGDIWHULSDGPLQLVWUDWLRQ,W
ZDV GHPRQVWUDWHG WKDW WKH PHWKDQROLF IUDFWLRQ LQGXFHV DQ LQFUHDVH LQ EUDLQ *$%$
FRQFHQWUDWLRQ>@
,Q DQ HDUO\ VWXG\ WKH QHXURVHGDWLYH HIIHFW RI EHUVDOGHJHQLQRUWKRDFHWDWH ZDV









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































/HLVKPDQLDVHV FRPSULVHV VHYHUDO GLVHDVHV WKDW DUH FDXVHG E\ SURWR]RDQ SDUDVLWHV IURP
RYHU@5%?.*'&%'#VSHFLHV7KHSURWR]RDDUHWUDQVPLWWHGE\WKHELWHRIIHPDOHSKOHERWRPLH
VDQGIOLHV
!"#$%&&'()*#DTXHRXVH[WUDFW WUHDWPHQW LQDFXWDQHRXV OHLVKPDQLDVLVSDWLHQWGHPRQVWUDWHG
QR IXUWKHU JURZWK DQG D VOLJKW GHFUHDVH LQ WKH DFWLYH OHVLRQ $W WKH HQG RI WKH GD\
WUHDWPHQW SHULRG WKH WR[LFRORJLFDO SDUDPHWHUV RI WKH SDWLHQW¶V VHUXP ZHUH ZLWKLQ WKH
UHIHUHQFHUDQJH>@,QPLFHWKHHIIHFWRIDQDTXHRXV!"#$%&&'()*H[WUDFWZDVLQYHVWLJDWHG
DIWHU RUDO E\ LQWUDJDVWULF LQWXEDWLRQ LY LQWUDSHULWRQHDO LS DQG WRSLFDO E\ UXEELQJ WKH
OHVLRQ VLWH DGPLQLVWUDWLRQ 7KHRUDO WUHDWPHQWZDVPRVW HIIHFWLYH DQGZDVDEOH WR SUHYHQW
DQGGHOD\ WKHRQVHWRI OHVLRQJURZWK LQDVXVWDLQHGPDQQHU$GGLWLRQDOO\DIWHURUDO LSRU
WRSLFDODSSOLFDWLRQ WKHSDUDVLWHVSHFLILFDQWLERG\ ,J* WLWHUZDV UHGXFHG WRFRPSDUHG
ZLWK XQWUHDWHG PLFH >@ )XUWKHU LQYHVWLJDWLRQV UHYHDOHG WKDW IODYRQRLGV SRVVHVVHG WKH
DQWLOHLVKPDQLDO DFWLYLW\ 4XHUFLWULQ KDG WKH KLJKHVW %&# 1%(+- DQWLOHLVKPDQLDO DFWLYLW\ DQG ORZ
F\WRWR[LFLW\ $ TXHUFHWLQ GLJO\FRVLGH ZDV WKH VHFRQGPRVW DFWLYH IODYRQRLG IROORZHG E\ LWV









ZHOO GLIIXVLRQ PHWKRG PLQLPXP LQKLELWRU\ FRQFHQWUDWLRQV 0,&V DUH VKRZQ LQ 7DEOH 
)XUWKHU LQYHVWLJDWLRQV UHYHDOHG ĮUKDPQRLVRURELQ DQG VHYHUDO IODYRQRLGV LQFOXGLQJ


















E\ LQKLELWLQJ (SVWHLQ%DUU YLUXV HDUO\ DQWLJHQ (%9($ DFWLYDWLRQ 7KHVH LQYHVWLJDWLRQV
LQGLFDWHG WKDW WKHRUWKRDFHWDWHPRLHW\ZDV LPSRUWDQW IRU WKHFKHPRSUHYHQWLYHDFWLYLW\
>@
7KH HIIHFW RI EXIDGLHQROLGHV DJDLQVW VHYHUDO WXPRU FHOOV ZDV WHVWHG LQ DQ %&# 1%(+- DVVD\
%U\RSK\OOLQ$VKRZHGDSRWHQWF\WRWR[LFLW\ LQKXPDQ OXQJFDUFLQRPD$FHOOV.%FHOOV
DQG FRORQ +&7 WXPRU FHOOV ZLWK (' YDOXHV RI   DQG  QJP/ UHVSHFWLYHO\
%HUVDOGHJHQLQDFHWDWH PDLQO\ GHPRQVWUDWHG DQ HIIHFW DJDLQVW +&7 FHOOV ('  




!"#$%&&'()* OHDISUHVV MXLFHSURGXFHGDQDQWLKLVWDPLQLFHIIHFW LQJXLQHDSLJV LOHXP %&#1%(+-






)XUWKHUPRUH PLFH ZHUH WUHDWHG ZLWK !"# $%&&'()* DTXHRXV OHDI H[WUDFWV GXULQJ D GD\
VHQVLWLVDWLRQRYDOEXPLQ29$SHULRG'DLO\RUDOWUHDWPHQWZLWKWKHOHDIH[WUDFWSURWHFWHGDOO
PLFHIURPIDWDODQDSK\ODFWLFVKRFN4XHUFLWULQKDGDSURWHFWLYHHIIHFWLQRIWKHDQLPDOV
DQGDSSHDUV WREH LPSRUWDQW IRU WKHDQWLDQDSK\ODFWLFHIIHFWRI WKHH[WUDFW)XUWKHUPRUH WKH

DTXHRXV OHDI H[WUDFW UHGXFHG HRVLQRSKLOLD DV ZHOO DV ,/ ,/ DQG 71)Į F\WRNLQH
SURGXFWLRQ >@ ,Q DGGLWLRQ WKH DTXHRXV H[WUDFW RI !"# $%&&'()* DQG TXHUFHWLQ EXW QRW





7KH SUHWUHDWPHQW RI JXLQHD SLJV ZLWK OHDI SUHVV MXLFH ZDV QRW DEOH WR SUHYHQW WKH
GHYHORSPHQW RI KLVWDPLQHLQGXFHG XOFHUDWLRQV >@ +RZHYHU WKH PHWKDQROLF IUDFWLRQ RI
!"#$%&&'()*# ZDV GHPRQVWUDWHG WR SRVVHVV DQWLXOFHU DFWLYLW\ LQ UDWV 7KH GHYHORSPHQW RI





WHVW PHWKRGPLFH ZHUH WUHDWHG ZLWK DTXHRXV H[WUDFW SULRU WR H[SRVXUH WR D KHDWLQGXFHG
QRFLFHSWLYH SDLQ VWLPXOXV KRW SODWH $ FKHPLFDO DQWLQRFLFHSWLYH PHWKRG REVHUYHG WKH
WULJJHUHGDEGRPLQDOFRQWUDFWLRQVLQPLFHDIWHULSLQMHFWLRQRIDFHWLFDFLG%RWKPHWKRGV
GHPRQVWUDWHGWKDWWKHDTXHRXVH[WUDFWSURYLGHGVLJQLILFDQWSURWHFWLRQDJDLQVWWKHQRFLFHSWLYH
VWLPXOXVFRPSDUHGZLWKGLFORIHQDF >@ ,QDGGLWLRQ WKHDQDOJHVLFSRWHQWLDORI WKHDTXHRXV
H[WUDFWPHWKDQROLFIUDFWLRQDQGDOVRRIDVWHURLGDOFRPSRXQGLQ!"#$%&&'()*ZDVH[DPLQHG
8VLQJ WKH FKHPLFDOPHWKRG GHVFULEHG DERYH WKH H[WUDFW DQG VWLJPDVWWULHQ














0DQ\ LQGLYLGXDOV VXIIHU IURPXUROLWKLDVLV7KHUHIRUH WKHDQWLXUROLWKLF DFWLYLW\ RI DQHWKDQROLF
H[WUDFW RI !"# $%&&'()* ZDV DVVHVVHG )UHVK XULQH IURP D PDQ ZDV PL[HG ZLWK GLIIHUHQW
FRQFHQWUDWLRQV RI WKH H[WUDFW EHIRUH VRGLXP R[DODWH VROXWLRQ ZDV DGGHG WR LQGXFH
FU\VWDOOLVDWLRQ$FRQFHQWUDWLRQGHSHQGHQWLQFUHDVHRIWKHQXPEHURIFU\VWDOVZDVREVHUYHG
+RZHYHUWKHVL]HRIFDOFLXPR[DODWHPRQRK\GUDWH&20FU\VWDOVZDVVLJQLILFDQWO\UHGXFHG
DQG HYHQ GLVDSSHDUHG WRWDOO\ ZLWK DQ H[WUDFW FRQFHQWUDWLRQ RI  PJP/ )XUWKHU WKH
IRUPDWLRQRIFDOFLXPR[DODWHGLK\GUDWH&2'FU\VWDOVZDVSURPRWHGUDWKHUWKDQ&20&2'




7R GHWHUPLQH WKH DQWLLQIODPPDWRU\ DFWLYLW\ WKH SDZ RHGHPD PHWKRG LQ :LVWDU UDWV ZDV
SHUIRUPHG 7KH DTXHRXV OHDI H[WUDFW VLJQLILFDQWO\ UHGXFHG SDZ RHGHPD LQIODPPDWLRQ >@
7KLVUHVXOWZDVFRQILUPHGLQDVHFRQGH[SHULPHQWUHYHDOLQJDVLJQLILFDQWUHGXFWLRQRIDFXWH






0DQ\ IODYRQRLGV DUH NQRZQ WR SRVVHVV DQ DQWLR[LGDQW HIIHFW 7KHUHIRUH WKH DQWLR[LGDQW
DFWLYLW\RIDTXHRXVOHDIH[WUDFWVDVZHOODVRITXHUFHWLQ2Į/DUDELQRS\UDQRV\OoĮ
/UKDPQRS\UDQRVLGH ZDV PHDVXUHG 7KH SODQWV XVHG IRU HWKDQROLF H[WUDFWV ZHUH JURZQ
XQGHU WKUHH GLIIHUHQW OLJKWV 7KH OLJKW WUHDWPHQWVZLWK HLWKHUZKLWH ODPSVZKLWH ODPSVSOXV
EOXHODPSVRUZKLWHODPSVSOXV89$ODPSVKDGQRVLJQLILFDQWLQIOXHQFHRQWKHWRWDOSKHQROLF
FRQWHQWRIWKHSURGXFHGH[WUDFWV8VLQJWKHGLSKHQ\OSLFU\OK\GUD]\O'33+IUHHUDGLFDO
PHWKRG WKH H[WUDFW WUHDWHG ZLWK DGGLWLRQDO EOXH ODPSV VKRZHG DQ LPSURYHG DQWLR[LGDQW











7KHHWKDQROLF OHDIH[WUDFWRI!"#$%&&'()* UHGXFHGZRXQGDUHDV LQ6SUDJXH'DZOH\








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 SUHJQDQW ZRPHQ !+,-$.,//)* JURXS ZLWK !"#$%&&'()*  FKHZDEOH WDEOHWV
GHPRQVWUDWHGQRVLGHHIIHFWVZKLFKZHUHDVVLJQHG WR WKHPHGLFDWLRQ >@$ IXUWKHUVWXG\
UHYHDOHG QR VLJQLILFDQW GLIIHUHQFH LQ REVHUYHG VLGH HIIHFWV 2QH ZRPDQ WUHDWHG ZLWK
!"#$%&&'()*  FKHZDEOH WDEOHWV VXIIHUHG IURP GLDUUKRHD DQG G\VHQWHU\ PD\EH GXH WR
ODFWRVH LQWROHUDQFH DQG D VHFRQG ZRPDQ KDG DQ H[DQWKHPD RI WKH IDFH DQG XSSHU
WKRUD[>@
,QD ORQJLWXGLQDOSURVSHFWLYH UDQGRPLVHGFRQWUROOHGDQLPDOVWXG\ WKHHIIHFWRI WKHPRWKHU




WKH PD[LPXP GDLO\ GRVH RI 07 UHVSHFWLYHO\ $IWHU  GD\V RI WUHDWPHQW ZHLJKW JDLQ
H[FOXGLQJ IRHWDODQGSODFHQWDOZHLJKWZDVKLJKHU LQJURXS% WKDQ LQJURXSV%&DQG




































































































































































































































































































































































































































































































































































































































































































































































































































































































































KDVEHHQ UHSRUWHGEDVHGRQ WKHFRQWDLQHGEXIDGLHQROLGHV$ WR[LFHIIHFWRI!"#$%&&'()* LQ
KXPDQLVQRWH[SHFWHGGXHWRWKHVPDOODPRXQWVRIEXIDGLHQROLGHV
7KH WR[LFLW\ WR FDWWOH KDV EHHQ GRFXPHQWHG LQ HDUOLHU VWXGLHV $ VWXG\ ZDV FRQGXFWHG
LQFOXGLQJ WZR FODYHV ZKLFK ZHUH WUHDWHG ZLWK IORZHU KHDGV RI !"# $%&&'()* &OLQLFDO
SDUDPHWHUVZHUHH[DPLQHGDIWHUDGPLQLVWUDWLRQRIJNJE\VWRPDFKWXEH)LYHKRXUVDIWHU
GRVLQJWKH\EHFDPHGHSUHVVHGDQGKDGUXPHQVWDVLVDVZHOODVDQRUH[LD7KHILUVWFDOIGLHG
DIWHU  K GXH WR G\VSQRHD WDFK\FDUGLD DQG H[FHHGHG KHDUW UDWH 7KH VHFRQG FDOI KDG
GLDUUKRHD IRU D ORQJ WLPH XQWLO LW GLHG DIWHU  K 7KLV VWXG\ GHPRQVWUDWHG D FRUUHODWLRQ
EHWZHHQEXIDGLHQROLGHVDQGWKHWR[LFHIIHFWLQFDWWOH>@




RI WKHPLFH >@$VLPLODUVWXG\ZDVSHUIRPHG LQFOXGLQJ6ZLVVDOELQRPLFH ,QWUDSHULWRQHDO
WUHDWPHQWZLWKDQDTXHRXVDQGPHWKDQROLFH[WUDFWDQGVKRZHG/'YDOXHV LQPLFHRI
DQGPJNJUHVSHFWLYHO\2UDOGRVHVVKRZHGQRWR[LFLW\XS WRJNJ LQPLFHDQGUDWV
>@ ,Q DGGLWLRQ LQWUDSHULWRQHDOO\ DGPLQLVWHUHGPHWKDQROLF IUDFWLRQ VKRZHG QR GHDWK XS WR
PJP/LQPLFHEXWWKHLUEHKDYLRXUFKDQJHGZLWKFRQFHQWUDWLRQV!PJP/>@


































































































































































































































































































































































































































































































































































































































































































































Please find the original figure on the homepage of the 
“Urology Care Foundation” (accessed June 2014): 
http://www.urologyhealth.org/urology/index.cfm?article=99 
 
In the University Library of Basel you will find the printed version of this 
thesis with the slightly modified figure. 
 
 
2.2 Human urinary bladder 
2.2.1 Bladder anatomy 
The urinary bladder is a musculomembranous organ in the pelvis. It is located above and 
behind the pubic bone. The position varies during empty and full bladder conditions and is 
also dependent on the condition of the rectum. 
The urinary bladder is composed of four surfaces: the superior, posterior, and two 
inferolateral surfaces. The superior surface is triangular, covered by peritoneum and slightly 
arched in the empty state. The posterior surface is covered 
by peritoneum in its superior region and the inferior region 
is covered by the endopelvic fascia of the rectovesical 
septum. The downward directed inferolateral surfaces point 
at the apex and are fully covered by endopelvic fascia (Fig. 
16). 
Additionally, the bladder includes the apex, fundus, neck, 
and body (between apex and fundus). The apex is directed 
toward the upper margin of the symphysis and is 
connected to the umbilicus by the median umbilical 
ligament. The fundus is the inferior region of the posterior 
wall and includes the trigone, which is firmly connected to the muscular coat. The trigone is 
always smooth even when the bladder is 
empty and is delineated by the two orifices 
of the ureters and the bladder neck, which 
is the most inferior region and connects 
the urethra to the urinary bladder (Fig. 17) 
[87,88]. 
The bladder wall is composed of four 
layers: mucosa, submucosa, muscularis 
propria, and adventitia/serosa (Fig. 18). 
The mucosa represents the innermost 
layer and contains the urothelium, which 
lines the renal pelvis, ureters, bladder and 
a portion of the urethra. It consists of a 
basal cell layer (attached to the basement membrane), an intermediate layer and a 
superficial layer. The latter contains umbrella, cells including uroplakins, which act as a 
barrier by reducing the permeability of the urothelium. Tight junctions, as well as the 
glycosaminoglycan (GAG) layer, which covers the umbrella cells, are assumed to contribute 
Figure 16. Lateral view of the urinary 
bladder [85]. 
 
Figure 17. Urinary bladder anatomy: female and male. 
Anterior view of frontal section [86]. 
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2.2.2 Urinary bladder function 
Q/! $&'!G+;/'@84! $&'!/':&)%/8!,)'!)'8:%/8+-*'!.%)! $&'!.+*$),$+%/!%.! $&'!-*%%;!$%!:)%;(0'!()+/'6!
R*%9')(*+! :)%;(0'! P2#! J! %.! 0%/0'/$),$';! .+*$),$'! ,! ;,@6! D+..')'/$! )'8%):$+%/! ,/;! 8'0)'$+%/!
:)%0'88'8! )';(0'! $&'! <%*(9'! %.! $&'! .+*$),$'! ,/;! ,*$')! +$8! 0%9:%8+$+%/6! S+/,**@4! $&'! G+;/'@8!
:)%;(0'!,/!,<'),>'!%.!P6T!J!()+/'!,!;,@!$&,$!+8!'?0)'$';!$&)%(>&!$&'!()'$')8!+/$%!$&'!-*,;;')6!
7&'! -*,;;')! +8! ,-*'! $%! ;+8$'/;! ,/;! 8$%)'! U##! C! "##!9J!%.! ()+/'! (/$+*! <%*(/$,)@!9+0$()+$+%/6!
V)+/'!'?+$8!$&'!-*,;;')!<+,!$&'!()'$&),4!=&+0&!+8!8&%)$')!+/!=%9'/!HT!09M!$&,/!+/!9'/!HN#!09M!
=&')'!$&'!()'$&),!+8!8())%(/;';!-@!$&'!:)%8$,$'!,/;!,*8%!)'*',8'8!8:')9,$%W%,!13N56!
X%)9,*! -*,;;')! .(/0$+%/! +/0*(;'8! $&'! 8$%),>'! ,/;! <%+;+/>Y9+0$()+$+%/! :&,8'84! =&+0&! ,)'!
)'>(*,$';! -@! ,! /'(),*! 0%/$)%*! 8@8$'9! +/! $&'! -),+/! ,/;! 8:+/,*! 0%);4! =&+0&! +/0*(;'8! $&'!








2.2.2.1 Storage phase 
$%&'()! *&+,-! ./%&(0-! 1-2-,1.! %,! .2+,()! &-3)-4!'-56(,+.'.! /6(/! (5/+7(/-! .8'2(/6-/+5! (,1!
.%'(/+5!2(/69(8.!/%!/6-!*&-/6&()!%*/)-/!(,1!.*22&-..!/6-!2(&(.8'2(/6-/+5!-45+/(/%&8!+'2*).-!
/%!/6-!*&+,(&8!:)(11-&!;<=>!
?6-!.8'2(/6-/+5! ./%&(0-! &-3)-4! +.! /&+00-&-1!:8!(33-&-,/! +'2*).-.! 3&%'! /6-!(5/+7(/-1!./&-/56!
&-5-2/%&.!7+(!2-)7+5!,-&7-.! /%! /6-!.2+,()!5%&1!(,1! 3*&/6-&! /%! /6-!@ABC!?6-!-33-&-,/!(5/+7+/8!
2(..-.!/6-!682%0(./&+5!,-&7-.!(,1!(5/+7(/-.!.8'2(/6-/+5!,-&7-.!3&%'!?#DEFDG!96+56!&-.*)/.!
+,! 1-/&*.%&!'*.5)-! &-)(4(/+%,! (,1! :)(11-&! ,-5H! 5%,/&(5/+%,! ;<I>C! ?6-&-3%&-G! /6-! :)(11-&! +.!
(:)-! /%! (55%''%1(/-! /6-! +,5&-(.-1!2&-..*&-! +,! /6-! :)(11-&! *,/+)! 7%+1+,0C!J11+/+%,())8G! /6-!
-4/-&,()! *&-/6&()! .26+,5/-&! +.! &-0*)(/-1! :8! /6-! .%'(/+5! ,-&7%*.! .8./-'! 7+(! /6-! 2*1-,1()!
,-&7-!/%!0*(&(,/--!.%'-!7%)*,/(&8!5%,/&%)!%7-&!7%+1+,0!(,1!5%,/+,-,5-!;<">C!
K*&+,0! /6-! ./%&(0-! 26(.-G! /6-! .8'2(/6-/+5! 2%./0(,0)+%,+5! ,-&7-.! &-)-(.-! ,%&(1&-,()+,-G!
96+56!(5/+7(/-.! +,6+:+/%&8!ȕLE(1&-,%5-2/%&.! +,!/6-!1-/&*.%&!'*.5)-C!?6+.!5%,.-M*-,/)8! )-(1.!
/%! :)(11-&! 9())! &-)(4(/+%,C! J11+/+%,())8 QRUDGUHQDOLQH ELQGV WR H[FLWDWRU\ Į#E(1&-,-&0+5!
&-5-2/%&.!+,!/6-!*&-/6&(!(,1!/6-!:)(11-&!,-5H!/%!5%,/&(5/!*&-/6&()!.'%%/6!'*.5)-!;<"G<N>C!?6-!




PJB6Q! &-)-(.-! +.! &-1*5-1! /%! 2&-7-,/! 1-/&*.%&! '*.5)-! 5%,/&(5/+%,C! R%9-7-&G! /6-! (33-&-,/!
(5/+7+/8!5%,./(,/)8!+,5&-(.-.!1*&+,0!/6-!:)(11-&!3+))+,0!26(.-!*,/+)!'+5/*&+/+%,!;<L>C!
!
2.2.2.2 Micturition reflex 
O,!(1*)/.G!'+5/*&+/+%,!+.!(!7%)*,/(&8!2&%5-..!(,1!+.!'-1+(/-1!:8!/6-!(5/+7(/+%,!%3!.*2&(.2+,()!
2(/69(8.!(,1! +,6+:+/+%,!%3! .8'2(/6-/+5!2(/69(8.C!J11+/+%,())8G! (!2&-&-M*+.+/-! 3%&! 7%+1+,0! +.!
/6-!&-)(4(/+%,!%3!/6-!-4/-&,()!*&-/6&()!.26+,5/-&!7+(!/6-!.%'(/+5!2*1-,1()!,-&7-.!;<I>C!
7KH UHIOH[ WR YRLG LV LQLWLDWHG E\ WZR GLIIHUHQW SDWKZD\V RI VPDOO P\HOLQDWHG $į DQG
XQP\HOLQDWHG&DIIHUHQWV$įDIIHUHQWVVHQGLQIRUPDWLRQDERXWWKHVWDWHRIEODGGHUIXOOQHVV
3&%'!./&-/56!&-5-2/%&.!+,!/6-!:)(11-&!9())!7+(!2-)7+5!,-&7-.!/%!/6-!.(5&()!.2+,()!5%&1!PSDES=Q!
(,1! ().%! 7+(! /6-! @JT! '(//-&! /%! /6-! @AB! P)%5(/-1! +,! /6-! &%./&()! 2%,/+,-! /-0'-,/*'QC!
?6-&-3%&-G!/6-!@AB!+.!(5/+7(/-1!(,1!-33-&-,/.!1-.5-,1!/6&%*06!/6-!.2+,()!5%&1!/%!(5/+7(/-!/6-!
.(5&()! 2(&(.8'2(/6-/+5! ,-&7-.! )-(1+,0! /%! 1-/&*.%&! 5%,/&(5/+%,.! (,1! :)(11-&! 7%+1+,0C!
A%&-%7-&G!/6-!+,6+:+/+%,!%3!/6-!)*':(&!.8'2(/6-/+5!(,1!.(5&()!2*1-,1()!,-&7-!,*5)-*.!&-.*)/.!
+,!/6-!&-)(4(/+%,!%3!/6-!:)(11-&!,-5H!(,1!-4/-&,()!*&-/6&()!.26+,5/-&G!&-.2-5/+7-)8!;<UG<<>C!




2(&(.8'2(/6-/+5! ,-&7-.! (,1! &-)-(.-! 3&%'! (! ,%,E,-*&%0-,+5! .%*&5-G! 96+56! '(8! :-! /6-!
*&%/6-)+*'! ;<L>C! JB6! +.! /6-! '%./! +'2%&/(,/! ,-*&%/&(,.'+//-&! &-.2%,.+:)-! 3%&! :)(11-&!
5%,/&(5/+%,!(,1!5(,!+,1*5-!'+5/*&+/+%,!1+&-5/)8!:8!(5/+,0!%,!(33-&-,/!,-&7-.!(,1!+,1+&-5/)8!:8!
&-)-(.+,0!%/6-&!'-1+(/%&.!;#VV>C!W,/+)!'+5/*&+/+%,G!/6-!*':&-))(!5-)).!&-)-(.-!JB6G!,+/&+5!%4+1-!
P$XQG! (,1!J?@G!96+56! ()/-&! /6-! -45+/(:+)+/8! %3! (33-&-,/! 3+:&-.! ;#V#>C! Y*&/6-&'%&-G! 7%+1+,0! +.!
+,1*5-1!:8!$X!&-)-(.-!+,!/6-!:)(11-&!%*/)-/G!96+56!)-(1.!/%!&-)(4(/+%,!;<">C!
S'%%/6! '*.5)-! 5%,/&(5/+%,.! 1-2-,1! %,! +,5&-(.-1! +,/&(5-))*)(&! 5()5+*'! 5%,5-,/&(/+%,.!
;B(DZ>+C!B()5+*'!+.!(:)-!/%!-,/-&!/6-!58/%.%)!7+(!FE/82-!B(DZ!56(,,-).!%&!/6&%*06!/6-!&-)-(.-!
3&%'! /6-!.(&5%2)(.'+5!&-/+5*)*'!PS[Q!7+(! O@L! &-5-2/%&.G!96+56! +.! /&+00-&-1!:8! +,%.+/%)E#G=GIE
/&+26%.26(/-! PO@LQC!J11+/+%,())8G! :)(11-&! ./&-/56+,0! +.!().%!(:)-! /%! +,1*5-!B(DZ! &-)-(.-! 3&%'!
/6-!S[C!?6-!S[! 5(,! &-0*)(/-! /6-! 5%,/&(5/+%,! 7+(!\Z! 56(,,-).! (,1!B(DZ! +,3)*4! /%! 1-5&-(.-!
;B(DZ>+C!
?6-! 26%.26%&8)(/+%,! 2(/69(8! +.! ().%! +'2%&/(,/! 3%&! 5%,/&(5/+%,C! B(DZ! 5%'2)-4-.! 9+/6!
5()'%1*)+,G! 96+56! (5/+7(/-.! '8%.+,! )+06/! 56(+,! H+,(.-! PAFB\QC! S*:.-M*-,/)8G! AFB\!
26%.26%&8)(/-.! /6-!'8%.+,! )+06/! 56(+,! PAFBQG!96+56! &-.*)/.! +,!AFBE@!(,1! .'%%/6!'*.5)-!
5%,/&(5/+%,!;<#>C!?6-!5%*,/-&(5/+,0!-,]8'-!AFBE26%.26(/(.-!1-26%.26%&8)(/-.!/6-!AFBE@!
(,1! +,1*5-.!'*.5)-! &-)(4(/+%,C! O,! (11+/+%,! /%! /6-!AFB\E2(/69(8G! /6-![6%EH+,(.-! P[XB\Q!
2(/69(8! &-0*)(/-.! 1-/&*.%&! 5%,/&(5/+%,! (,1! +.! +,1-2-,1-,/! 3&%'! B(DZ! +,5&-(.-.C! [XB\!
+,6+:+/.! /6-! AFBE26%.26(/(.-G! .-,.+/+.-.! /6-! 1-/&*.%&! /%! 5()5+*'! (,1! +,1*5-.! 5%,/&(5/+%,!
;<"G#VD>C!
^(&+%*.! &-5-2/%&.! 5(,! +,+/+(/-! /6-! 2&-7+%*.)8! 1-.5&+:-1! 2(/69(8.! /%! +,1*5-! :)(11-&!
5%,/&(5/+%,C!
!
Muscarinic acetylcholine receptors 
A*.5(&+,+5! (5-/8)56%)+,-! &-5-2/%&.! :-)%,0! /%! /6-!TE2&%/-+,E5%*2)-1! &-5-2/%&! 3('+)8C! O,! /6-!
6*'(,!:)(11-&G!/6-!-45+/(/%&8!A#G!ALG!(,1!AI!'*.5(&+,+5!&-5-2/%&.!P5%*2)-1!/%!TM_##Q!(,1!/6-!
+,6+:+/%&8!AD!(,1!A=!.*:/82-.!P5%*2)-1!/%!T+_%Q!6(7-!:--,!1-3+,-1C!
O,! /6-! 6*'(,! 1-/&*.%&G! /6-!AD! .*:/82-! 2&-1%'+,(/-.G! :*/!AL! &-5-2/%&! ./+'*)(/+%,! :8!JB6!
(22-(&.!/%!:-!/6-!'%./!+'2%&/(,/!3%&!1-/&*.%&!5%,/&(5/+%,C!?6-!(5/+7(/+%,!%3!/6-!&-5-2/%&G!(,1!
/6*.! TM_##G! *2E&-0*)(/-.! 26%.26%)+2(.-! B! P@FBQ! (,1! )-(1.! /%! 26%.26%+,%.+/+1-! 681&%)8.+.G!
0-,-&(/+,0! O@L! (,1! #GDE1+(58)0)85-&+,-! PKJTQG! 96+56! &-.*)/.! +,! /6-! +,3)*4! %3! -4/&(5-))*)(&!
5()5+*'!(.!9-))!(.!/6-!&-)-(.-!%3!B(DZ!3&%'!+,/&(5-))*)(&!./%&-.C!?6+.!+,5&-(.-1!;B(DZ>+!)-(1.!/%!
'*.5)-! 5%,/&(5/+%,! ;<"G#VL>C! O,! (11+/+%,G! :%/6! /6-! AFB\E1-2-,1-,/! 2(/69(8! (,1! [XB\!




The M2 and M4 receptors initiate an additional pathway. These receptors bind to pertussis 
toxin-sensitive Gi/o. and inhibit adenylyl cyclase (AC), inhibiting the cyclic AMP-induced 
relaxation [91]. 
In the urothelium, M2 receptors are only expressed in the umbrella cells, whereas the M3, M4, 
and M5 receptors are expressed throughout the urothelium and detrusor muscle cells. The 
activation of the urothelial muscarinic receptors by an agonist induces the release of ATP 




Figure 19. Detrusor muscle contraction induced by the activation of M3 muscarinic receptor signalling. ACh, acetylcholine; PLC, 
phospholipase C; DAG, diacylglycerol; IP3, inositol-trisphosphate; PKC, protein kinase C; MLC, myosin light chain; SR, 
sarcoplasmic reticulum; CIC, calcium-induced calcium release. The activation of M3 receptor by ACh induces Ca
2+
 influx via L-
type Ca
2+
 channels and calcium release from the SR. The Rock pathway and MLCK-dependent pathway are briefly illustrated. 





ĮEJ1&-,%5-2/%&.! (&-! 2&+'(&+)8! -42&-..-1! +,! /6-! :)(11-&! ,-5H! (,1! *&-/6&(G! :*/! (&-! %,)8!
'%1-&(/-)8! -42&-..-1! +,! /6-! GHWUXVRU DQG EODGGHU GRPH Į#EJ1&-,%5-2/%&.! (&-! 2&+'(&+)8!
-42&-..-1! +,! '-,G! .2-5+3+DOO\ LQ WKH SURVWDWH ZKHUHDV ĮDE(1&-,%5-2/%&.! (&-! 2&+'(&+)8!
-42&-..-1! +,! 9%'-,C! 6WLPXODWLRQ RI WKH Į#E(1&-,%5-2/%&.! (5/+7(/-.! @FBG! 96+56! )-(1.! /%!
EODGGHU FRQWUDFWLOLW\ ĮDEJ1&-,%5-2/%&.! +,6+:+/! /6-! &-)-(.-! %3! ,%&(1&-,()+,-! (,1! +,1*5-!




2.3 Overactive bladder syndrome 
2.3.1 Pathophysiology 
X7-&(5/+7-! :)(11-&! .8,1&%'-! PXJaQ! +.! (! .8'2/%'(/+5! 1+(0,%.+.! /6(/! 9(.! 1-3+,-1! :8! /6-!
O,/-&,(/+%,()!B%,/+,-,5-!S%5+-/8!POBSQ!(.!*&+,(&8!*&0-,58G!9+/6!%&!9+/6%*/!*&0-!+,5%,/+,-,5-G!
*.*())8! 9+/6! 3&-M*-,58! (,1! ,%5/*&+(G! (3/-&! /6-! -45)*.+%,! %3! *&+,(&8! /&(5/! +,3-5/+%,! PW?OQ! %&!
%/6-&! %:7+%*.! 2(/6%)%08! ;#VI>C! X7-&(5/+7-! :)(11-&! +.! (! .8'2/%'(/+5! .8,1&%'-! 9+/6%*/! (!
1-3+,+/+7-!(-/+%)%08!%&!2(/6%268.+%)%08C!W&0-,58!+.!/6-!5%&,-&./%,-!.8'2/%'!%3!XJaG!96+56!
+.!1-3+,-1!(.!/6-!.*11-,!5%'2-))+,0!1-.+&-!/%!'+5/*&(/-!/6(/!+.!1+33+5*)/!/%!1-)(8C!
O,!5%,/&(./G!1-/&*.%&!%7-&(5/+7+/8! PKXQ! +.!1+(0,%.-1!*.+,0!*&%18,('+5!./*1+-.!(,1! +,5)*1-.!
+,7%)*,/(&8!1-/&*.%&!5%,/&(5/+%,.!1*&+,0!/6-!3+))+,0!26(.-C!K-/&*.%&!%7-&(5/+7+/8!+.!5(/-0%&+.-1!
+,/%!+1+%2(/6+5!KX!(,1!,-*&%0-,+5!KX!;#V">C!
S-7-&()! 682%/6-.-.! 6(7-! :--,! 2&%2%.-1! /%! -42)(+,! /6-! %&+0+,! %3! XJa! 2(/6%268.+%)%08!
+,5)*1+,0!/6-!'8%0-,+5G!,-*&%0-,+5G!(,1!(*/%,%'8!/6-%&+-.!;#VN>C!
!
2.3.1.1 The myogenic theory 
?6-!'8%0-,+5!/6-%&8!.*00-./.!/6(/!/6-&-!(&-!56(,0-.!+,!/6-!2&%2-&/+-.!%3!1-/&*.%&!'8%58/-.!
+,!KX!2(/+-,/.G!5%'2(&-1!9+/6!,%&'()!1-/&*.%&!'8%58/-.C!@(&/+()!1-,-&7(/+%,!%3!/6-!1-/&*.%&!
)-(1.! /%! (,! ()/-&(/+%,! %3! .'%%/6! '*.5)-! 2&%2-&/+-.G! +,5)*1+,0! (,! +,5&-(.-1! .2%,/(,-%*.!
(5/+7+/8! (,1! -)-5/&+5()! 5%*2)+,0! :-/9--,! /6-! .'%%/6! '*.5)-! 5-)).C! ?6-&-3%&-G! -45+/(/+%,!
.2&-(1.! /%! (33-5/! (! )(&0-&! &-0+%,! %3! /6-! :)(11-&! 9())! (,1! &-.*)/.! +,! /6-! 5%,/+,*%*.! &+.-! %3!
+,/&(7-.+5()!2&-..*&-C!J11+/+%,())8G!)%5()!5%,/&(5/+%,.!%3!.%'-!.'%%/6!'*.5)-.!(&-!5(*.-1!:8!
/6-! ./&-/56+,0! %3! 2(&/.! %3! /6-! :)(11-&!9())! (,1! /6-! .*:.-M*-,/)8! (5/+7(/-1! ./&-/56E.-,.+/+7-!




2.3.1.2 The neurogenic theory 




()/-&(/+%,.! +,5)*1-! (! &-1*5/+%,! +,! 2-&+26-&()! %&! 5-,/&()! +,6+:+/+%,G! (,! -,6(,5-'-,/! %3!
-45+/(/%&8! /&(,.'+..+%,! +,! /6-! '+5/*&+/+%,! &-3)-4! 2(/69(8G! +,5&-(.-1! 2&+'(&8! (33-&-,/! +,2*/!
3&%'! /6-! )%9-&!*&+,(&8! /&(5/! PFW?QG!(,1!-'-&0-,5-!%3!:)(11-&! &-3)-4-.! /6(/!(&-! &-.+./(,/! /%!
5-,/&()!+,6+:+/+%,!;<=@%HVLGH$įDIIHUHQWVDVHFRQGSDWKZD\+.!+,7%)7-1!/6(/!+.!'-1+(/-1!:8!
!""!
BE3+:&-.C!BE3+:&-.! (&-! 2&+'(&+)8! +,7%)7-1! +,! 2(+,! .-,.(/+%,! 1*&+,0! 1+.-(.-C!B! (33-&-,/.!'(8!
+,1*5-! /6-! .2+,()! .-0'-,/()! &-3)-4! 2(/69(8G!96+56! +.! &-.2%,.+:)-! 3%&! 1-/&*.%&! 5%,/&(5/+%,.!
(,1! ,-*&%0-,+5! KX! ;<<>C! O,! (11+/+%,G! /6-! +,6+:+/+%,! %3! .8'2(/6-/+5! +,,-&7(/+%,! :8! .*&0+5()!
+,/-&&*2/+%,! %&! 26(&'(5%)%0+5()! /&-(/'-,/! 6(.! :--,! 2&%7-,! /%! &-1*5-! *&-/6&()! %*/3)%9!
&-.+./(,5-G!:)(11-&!5(2(5+/8!(,1!+,5&-(.-!/6-!3&-M*-,58!(,1!+,/-,.+/8!%3!:)(11-&!5%,/&(5/+%,.!
;#V<>C! @(/+-,/.! .*33-&+,0! 3&%'! ,-*&%)%0+5! 1+.-(.-.! %3/-,! -46+:+/! XJaC! $-*&%)%0+5! 1+.-(.-.!
DUH FDWHJRULVHG LQWR VXSUDVSLQDO 3DUNLQVRQ¶V GLVHDVH FHUHEUDO SDOV\ VSLQDO VSLQDO 5%&1!
+,b*&8G! .2+,()! ./-,%.+.QG! .*2&(.(5&()! P1-/&*.%&! .26+,5/-&! 18.8,-&0+(QG! 2-&+26-&()! P1+(:-/-.!
'-))+/*.G!6-&2-.!]%./-&QG!(,1!'+4-1!;<I>C!
!
2.3.1.3 The autonomy theory 
?6-!(*/%,%'8!/6-%&8!(//-'2/.!/%!1-.5&+:-!/6-!5(*.-!%3!%7-&(5/+7-!:)(11-&!:-5(*.-!,-+/6-&!
/6-! '8%0-,+5! ,%&! /6-! ,-*&%)%0+5! /6-%&8! 3*))8! (55%*,/.! 3%&! ())! &-5%0,+.-1! 5)+,+5()! (,1!
-42-&+'-,/()! 3+,1+,0.C! ?6+.! ,-9! 682%/6-.+.! +.! :(.-1! %,! %:.-&7(/+%,.! %3!'*.5)-! (5/+7(/+%,!
2&%5-..-.!9+/6+,! /6-!0(./&%+,/-./+,()! /&(5/C!?6-!(*/%,%'8!/6-%&8!.*00-./.!/6(/! /6-!1-/&*.%&!
'*.5)-! +.! (&&(,0-1! +,/%! '%1*)-.G! 96+56! (&-! (5/+7-! 1*&+,0! /6-! 3+))+,0! 26(.-C! J! 2-&+26-&()!
'8%7-.+5()! 2)-4*.G! 5%,.+./+,0! %3! +,/-&./+/+()! 5-)).! (,1! +,/&('*&()! 0(,0)+(G! 5%,/&%).! /6-.-!
5+&5*'.5&+:-1! (&-(.! %3! '*.5)-C! O,/&('*&()! 0(,0)+(! (&-! (:)-! /%! &-5-+7-! +,2*/.! 3&%'!
,-+06:%*&+,0!'%1*)-.G!2-)7+5!%&0(,.G!(33-&-,/!5%))(/-&().G!(,1!+,/-&./+/+()!5-)).C!?6-!(5/+7(/+%,!
%3! (! .+,0)-! '%1*)-! &-.*)/.! +,! '+5&%'%/+%,.G! 96+)-! /6-! 5%,/&(5/+%,! %3! '*)/+2)-! '%1*)-.!
2&%1*5-.! '(5&%.5%2+5! '%7-'-,/.! &-.*)/+,0! +,! /6-! 5%,/&(5/+%,! %3! /6-! -,/+&-! :)(11-&C! ?6-!
.8,56&%,+.(/+%,!%3!())!%3!/6-!'%1*)-.!:8!/6-!+,/&('*&()!,-&7-!%&!+,/-&./+/+()!5-))!,-/9%&H.!'(8!
+,1*5-!:)(11-&!7%+1+,0G!(.!+/!%55*&.!(3/-&!B$S!./+'*)(/+%,!%3!/6-!1-/&*.%&C!









S-7-&()! ./*1+-.! 9-&-! 2-&3%&'-1! :(.-1! %,! /6-! XJa! 1-3+,+/+%,! 2&%7+1-1! :8! /6-! OBSC! ?6-!
$(/+%,()! X7-&(5/+7-! a)(11-&! c7()*(/+%,! P$XaFcQ! 2&%0&('! +,7-./+0(/-1! /6-! 2&-7()-,5-! %3!
XJaG!9+/6! %&!9+/6%*/! *&0-! +,5%,/+,-,5-G! +,! /6-!W,+/-1!S/(/-.! (1*)/! 2%2*)(/+%,C!?6-! %7-&())!
2&-7()-,5-! %3!XJa!9(.! #"CVd! 3%&!'-,! (,1! #"C<d! 3%&! 9%'-,C! O,1-2-,1-,/! %3! (0-G!'-,!
!"N!




'-,! ;##L>C! O,! DVVUG! /6-! 9%&)19+1-!XJa! 2&-7()-,5-!9(.! -./+'(/-1! /%! :-! #VCNdG! 96+56! +.!
-42-5/-1! /%! &+.-! /%! DVC#d! +,! DV#U! ;##=>C! J)/6%*06! XJa! 2&-7()-,5-! &(/-.! (&-! .+'+)(&! +,!
9%'-,! (,1! '-,G! /6-&-! (&-! 0-,1-&! 1+33-&-,5-.! /6(/! (&-! %:.-&7-1! +,! (0-E.2-5+3+5! 0&%*2.C!
e%'-,! 6(7-! (! 6+06-&! 2&-7()-,5-! %3!XJa! .8'2/%'.! :-3%&-! /6-! (0-! %3! "VG!96-&-(.!'-,!
6(7-!(!6+06-&!2&-7()-,5-!(3/-&!(0-!"V!;##L>C!
?6-! ,-0(/+7-! +'2(5/! %3! *&0-! (,1! *&0-! +,5%,/+,-,5-! %,! /6-! 6-()/6E&-)(/-1! M*()+/8! %3! )+3-!
PR[fFQ! +.! 5%,.+1-&-1! /%! :-!'%&-! .+0,+3+5(,/! 5%'2(&-1!9+/6! 3&-M*-,58! (,1! ,%5/*&+(C! W&0-!
DQG XULQDU\ LQFRQWLQHQFH FDQ LQIOXHQFH SDWLHQWV¶ SK\VLFDO VRFLDO DQG SV\FKROR0+5()! 9-))E
:-+,0! (.!9-))! (.! .-4*()! (,1! -7-&81(8! (5/+7+/+-.C! R%9-7-&G! XJa!9+/6%*/! +,5%,/+,-,5-! ().%!
./&%,0)8!+'2(5/.!M*()+/8!%3!)+3-!Pf%FQG!1-2-,1+,0!%,!/6-!,*':-&!%3!7%+1.!1*&+,0!/6-!1(8!(,1!
,+06/)8!(9(H-,+,0.C!J! ./*18! +,! /6-!WS!(.H-1!<#<!2(&/+5+2(,/.!(:%*/! /6-+&!XJa!.8'2/%'.G!
1-2&-..+%,! .8'2/%'.G! (,1! .)--2! 1+./*&:(,5-! :(.-1! %,! 7()+1(/-1! .5()-.C! ?6-! &-.*)/.!
5%,3+&'-1! /6(/!2(/+-,/.!9+/6! +,5%,/+,-,5-!6(1! /6-!6+06-./! +'2(5/-1!f%FC!@(/+-,/.!.*33-&+,0!
3&%'! *&0-,58! &-2%&/-1! (! 6+06-&! f%F! +'2(5/! 5%'2(&-1! 9+/6! /6%.-! 9+/6%*/C! J11+/+%,())8G!
IUHTXHQF\DQGQRFWXULDKDGDQHJDWLYHLQIOXHQFHRQSDWLHQWV¶4R/>###>C!!
!
Estimated financial impact 
?6-!+,7-./+0(/+%,!+,/%!/6-!3+,(,5+()!+'2(5/!%3!XJa!3%&!2(/+-,/.!(,1!2*:)+5!6-()/65(&-!.8./-'.!
+.!(!1+33+5*)/!/(.HC!?6-!$XaFc!2&%0&('!-./+'(/-1!-5%,%'+5!5%./.!:(.-1!%,!M*-./+%,.!(:%*/!



















9(.6E/-./C! J! 2(1! /-./! +.! (1'+,+./-&-1! /6(/! 2&%7%H-.! 1-/&*.%&! 5%,/&(5/+%,! 96+)-! /6-! 2(/+-,/!
9(.6-.! /6-+&! 6(,1.!9+/6! 5%)1!9(/-&! 3%&! %,-!'+,*/-C!?6+.!,%,E+,7(.+7-!'-/6%1!5(,!5%,3+&'!
(,1! M*(,/+38! *&+,-! )-(H(0-`! 6%9-7-&G! +/! +.! ,%/! '(,1(/%&8! 3%&! /6-! 1+(0,%.+.! %3! XJaC!
W&%18,('+5! -4('+,(/+%,.! (&-! &-5%''-,1-1! +,! 2(/+-,/.! 9+/6! 5%'2)-4! .8'2/%'.G!
,-*&%)%0+5()! 1+.%&1-&.! (,1!96-,! 5%,.-&7(/+7-! /6-&(2+-.! 6(7-! 3(+)-1! ;##N>C! O,! 9%'-,G! +/! +.!
+'2%&/(,/! /%! +,5)*1-! (! 08,(-5%)%0+5()! (,1! %:./-/&+5! 6+./%&8! (.! 9-))! (.! 3%&'-&! .*&0-&+-.C!
K-2-,1+,0! %,! /6-! 1+(0,%.+.G! 2(/+-,/.! 6(7-! 1+33-&-,/! /&-(/'-,/! %2/+%,.C! ?6-! (7(+)(:)-!
/&-(/'-,/! %2/+%,.! ())-7+(/-! XJa! .8'2/%'.! :8! 1-5&-(.+,0! *&0-,58G! &-1*5+,0! *&+,(&8! *&0-!
+,5%,/+,-,5-G!(,1!+,5&-(.+,0!/6-!7%+1-1!7%)*'-!;##">C!
!
2.3.4 Non-pharmacological therapies 
?6-!3+&./!./-2.!%3!5%,.-&7(/+7-!/&-(/'-,/.! +,5)*1-!56(,0-.!+,! )+3-./8)-G!:)(11-&!/&(+,+,0G!(,1!
2-)7+5!3)%%&!'*.5)-!-4-&5+.-.C!
@(/+-,/.!.6%*)1!(7%+1! 5(33-+,-G! ()5%6%)G! (,1!6%/! .2+5-.!1*-! /%! /6-+&! +&&+/(/+,0!-33-5/.!%,! /6-!
:)(11-&!'*5%.(C! O,! %:-.-! 2(/+-,/.G! 9-+06/! )%..! 5(,! +'2&%7-! *&0-,58! .8'2/%'.C! @(/+-,/.!
.*33-&+,0! 3&%'!,%5/*&+(! .6%*)1!(7%+1!1&+,H+,0! 3)*+1.!(3/-&! "hVV!2'!(,1!7%+1!:-3%&-!0%+,0! /%!
.)--2C!!
a)(11-&! /&(+,+,0!6-)2.! /%!.*22&-..! +,7%)*,/(&8!1-/&*.%&!5%,/&(5/+%,.!(,1!5(,!(56+-7-! )%,0E
/-&'!-33-5/.!(.!)%,0!(.!/6-!2(/+-,/.!5%,/+,*-!-4-&5+.+,0C!Y%&!/+'-1!'+5/*&+/+%,G!%,-!/-56,+M*-!
+,!/6-!:)(11-&!&-E-1*5(/+%,G!2(/+-,/.!(&-!(17+.-1!/%!7%+1!(55%&1+,0!/%!/6-+&!)%,0-./!'+5/*&+/+%,!
+,/-&7()C!c(56!9--HG! /6-!1*&(/+%,!:-/9--,!7%+1.! +.! +,5&-'-,/())8! 2&%)%,0-1! 3%&! #V!'+,*/-.!
*,/+)! /6-!2(/+-,/! +.!.(/+.3+-1!9+/6! /6-!&-.*)/.C!J11+/+%,())8G!2-)7+5! 3)%%&!-4-&5+.-.!5(,! +'2&%7-!
.8'2/%'.!:8!5%,/&(5/+,0!(,1!&-)(4+,0!/6-!'*.5)-.!;##">C!
J,%/6-&!()/-&,(/+7-!/6-&(28!%2/+%,!'(8!:-!(5*2*,5/*&-C!O/!+.!9%&/6!/%!&-5%''-,1!/%!2(/+-,/.!
9+/6!'%/+7(/+%,!(,1! +,/-&-./! +,!5%'2)-'-,/(&8!(,1!()/-&,(/+7-!'-1+5+,-G! /%!,%,E&-.2%,1-&.!




2.3.5 Pharmacological therapies 
S-7-&()! 1+33-&-,/)8! (5/+,0! 1&*0.! (&-! (1'+,+./-&-1! /%! 2(/+-,/.! 3%&! /6-! /&-(/'-,/! %3! XJaC!
A*.5(&+,+5! &-5-2/%&! (,/(0%,+./.! (&-! /6-! 3+&./E)+,-! 26(&'(5%/6-&(28! 3%&!XJa! .8,1&%'-!(,1!
*&+,(&8! +,5%,/+,-,5-C! a-.+1-.G! %/6-&! 1&*0.! +,5)*1+,0! 5()5+*'! (,/(0%,+./.G! .-&%/%,+,! (,1!
,%&(1&-,()+,-! &-*2/(H-! +,6+:+/%&.G! (,1! -./&%0-,.! (.! 9-))! (.! +,/&(7-.+5()! +,b-5/+%,! %3!
:%/*)+,*'/%4+,!(&-!*.-1!/%!&-1*5-!XJa!.8'2/%'.C!
!
Muscarinic receptor antagonists 
J,/+'*.5(&+,+5.! (5/! 1*&+,0! /6-! ./%&(0-! 26(.-! (,1! 6(7-! ()'%./! ,%! -33-5/! %,! 7%+1+,0!
5%,/&(5/+%,.! ;##<>C! J,/+56%)+,-&0+5.! 1-5&-(.-! /6-! +,/-,.+/8! %3! 5%,/&(5/+%,.! (.! 9-))! (.!
1-5&-(.-!3&-M*-,58G!+'2&%7-!:)(11-&!5(2(5+/8G!(,1!&-1*5-!*&0-,58C!
A*.5(&+,+5! &-5-2/%&.! (&-! -42&-..-1! ,%/! %,)8! +,! /6-! :)(11-&! :*/! ().%! +,! %/6-&! 2(&/.! %3! /6-!
:%18G!.*56!(.! /6-!:&(+,G!.()+7(&8!0)(,1.G!6-(&/!'*.5)-!%&! +,/-./+,-G!96+56!-42)(+,.!'(,8!%3!
/6-+&! .+1-! -33-5/.C! ?82+5()! (,/+'*.5(&+,+5! 1&*0! .+1-! -33-5/.! (&-! 1&8! -8-.! (,1! '%*/6G!




























?%)/-&%1+,-! K-/&*.+/%)i!S[![-/!B(2.!D!'0G!=!'0! #!4!=!'0! A#EAI!




S%)+3-,(5+,! ^-.+5(&-i!?(:!I!'0G!#V!'0! #!4!I!E!#V!'0! AL!




X48:*/8,+,! 6(.! 7(&+%*.! 26(&'(5%)%0+5()! 2&%2-&/+-.G! .*56! (.! (,/+56%)+,-&0+5G! )%5()!
(,(-./6-/+5G! 1+&-5/! '*.5)-! &-)(4(,/G! (,1! (,/+6+./('+,+5! (5/+7+/+-.C! O/! 6(.! (! 9-))E2&%7-,!
-33+5(58G! :*/! *,3%&/*,(/-)8G! ().%! 6(.! .-7-&-! (,/+56%)+,-&0+5! .+1-! -33-5/.C! X48:*/8,+,! +.!





?%)/-&%1+,-! 6(.! ,%! .-)-5/+7+/8! 3%&! (! &-5-2/%&! .*:/82-G! :*/! 6(.!'%&-! (33+,+/8! 3%&! /6-! :)(11-&!
'*.5(&+,+5!&-5-2/%&.!/6(,!.()+7(&8!0)(,1!&-5-2/%&.C!?6-!)+7-&!'-/(:%)+.-.!/%)/-&%1+,-! +,/%!+/.!
'-/(:%)+/-G!IER?G!96+56!6(.!5%'2(&(:)-!(5/+7+/8C!J!)(&0-!&(,1%'+.-1G!1%*:)-E:)+,1!2)(5-:%E
5%,/&%))-1! /&+()!1-'%,./&(/-1! /6-!-33+5(58!(,1!/%)-&(:+)+/8!%3! /%)/-&%1+,-! O[!(,1!c[G!96-&-:8!






Y-.%/-&%1+,-! +.! (! 2&%1&*0! /6(/! +.! ().%! '-/(:%)+.-1! +,/%! IER?C! Y-.%/-&%1+,-! '-/(:%)+.'!
+,7%)7-.!2-&+26-&()!-./-&(.-.!(,1!*,1-&0%-.!)+//)-!6-2(/+5!'-/(:%)+.'! ;#DV>C!J!1%*:)-E:)+,1!
2)(5-:%E5%,/&%))-1! /&(+)! +,7-./+0(/-1! /6-! -33-5/! %3! 3-.%/-&%1+,-! U!'0! +,! 2(/+-,/.! &-.2%,1+,0!













O,! (! 2)(5-:%E! (,1! /%)/-&%1+,-E5%,/&%))-1! 26(.-! OO! 1%.-E3+,1+,0! ./*18G! .%)+3-,(5+,!
1-'%,./&(/-1!/6-!:-./!-33+5(58G!M*()+/8!%3!)+3-G!(,1!/%)-&(:+)+/8!(/!1(+)8!1%.-.!%3!I!(,1!#V!'0!






1%*:)-E:)+,1! 2)(5-:%E5%,/&%))-1G! 2(&())-)E0&%*2! ./*18C! @(/+-,/.! /%%H! 1(&+3-,(5+,! %,5-! 1(+)8!
96-&-:8!'+5/*&+/+%,! 3&-M*-,58G!:)(11-&!5(2(5+/8G! 3&-M*-,58!(,1!.-7-&+/8!%3!*&0-,58!(.!9-))!
(.! ,*':-&! %3! +,5%,/+,-,5-! -2+.%1-.! 9-&-! .+0,+3+5(,/)8! +'2&%7-1C! R%9-7-&G! /6-&-! 9(.! ,%!
56(,0-! +,! ,%5/*&+(C! ?6-! %:.-&7-1! .+1-! -33-5/.! 9-&-! '+)1! /%! '%1-&(/-! (,1! ,-+/6-&! .6%9!
:)*&&-1!7+.+%,!,%&!5(&1+(5!%&!B$S!&-)(/-1!(17-&.-!-7-,/.!;#D<>C!K(&+3-,(5+,!+.!.*00-./-1!/%!








%,!.'%%/6!'*.5)-! +.! +,1*5-1!:8!'%1-&(/-!FE/82-!B(DZ!56(,,-)! +,6+:+/+%,G! )%5()!(,(-./6-/+5!
(5/+7+/8G! (,1! 26%.26%1+-./-&(.-! +,6+:+/+%,! ;#L#>C! J! 1%*:)-E:)+,1! 5&%..%7-&! ./*18!
1-'%,./&(/-1! 5%'2(&(:)-! -33+5(58! 3%&! &-1*5+,0! *&0-,58G! 3&-M*-,58G! (,1! +,5%,/+,-,5-!
-2+.%1-C!Y*&/6-&'%&-G!3)(7%4(/-!9(.!(..%5+(/-1!9+/6!3-9-&!(,1!'+)1-&!.+1-!-33-5/.!;#LD>C!
!








O,! DV#=G! /6-! 3+&./! ȕLE(0%,+./! (0-,/G! '+&(:-0&%,! Pa-/'+0(iQG! 9(.! (22&%7-1! 3%&! /6-! *.-! +,!
S9+/]-&)(,1! (,1! 9(.! +,1+5(/-1! 3%&! XJaC! J! &(,1%'+.-1G! 1%*:)-E:)+,1! 26(.-! OOO! ./*18!
1-'%,./&(/-1! (! .+0,+3+5(,/! '+5/*&+/+%,! 3&-M*-,58! 1-5&-(.-! %7-&! D=6! (,1! 1-5&-(.-1!
+,5%,/+,-,5-!-7-,/.!(.!9-))!(.!+'2&%7-1!f%FC!K*&+,0!(!#DE9--H!/&-(/'-,/G!1%.-.!%3!IV!'0!
%&! #VV! '0! %,5-! 1(+)8! 9-&-! 9-))! /%)-&(/-1! 9+/6! 1&8! '%*/6! (17-&.-! -7-,/.! %:.-&7-1! (/!
5%'2(&(:)-!)-7-).!9+/6!2)(5-:%!;#L=>C!
J!&(,1%'+.-1G!1%*:)-E:)+,1!26(.-!OO! /&+()! +,7-./+0(/-1!/6-!-33-5/!%3! /6-! /&-(/'-,/!5%':+,+,0!
'+&(:-0&%,!(,1!.%)+3-,(5+,!5%'2(&-1!/%!/6-!'%,%/6-&(28!9+/6!.%)+3-,(5+,!I!'0C!?6-!7%)*'-!
7%+1-1!2-&!'+5/*&+/+%,!9(.!+,5&-(.-1!+,!())!5%':+,(/+%,!0&%*2.C!J).%!/6-!'+5/*&+/+%,!3&-M*-,58!






(! )%5()! (,(-./6-/+5! -33-5/! %,! ,-&7-! /-&'+,().C! O'+2&('+,-! +,6+:+/.! ,-*&%,()! &-*2/(H-! %3!
.-&%/%,+,! (,1! ,%&(1&-,(+),-C! ?6-! '*.5)-! &-)(4(,/! -33-5/! +.! '%./! 2&%:(:)8! -4-&/-1! :8! /6-!
GUXJ¶V! +,3)*-,5-! %,! (1&-,%5-2/%&.! (,1! 2&%1*5-.! (,! +,5&-(.-1! %*/3)%9! &-.+./(,5-! +,! /6-!
:)(11-&!:(.-!(,1!*&-/6&()!.'%%/6!'*.5)-!;##"G#D=>C!J)/6%*06!+'+2&('+,-!.6%*)1!:-!5(&-3*))8!
2&-.5&+:-1G!/6-!/&-(/'-,/!%3!-)1-&)8!2(/+-,/.!9+/6!*&+,(&8!+,5%,/+,-,5-!(,1!1-/&*.%&!+,./(:+)+/8!





-33-5/! %3! /6-! %-./&%0-,! /6-&(28! %,! XJa! +,! 2%./'-,%2(*.()! 9%'-,C! F%5())8! (22)+-1!
%-./&%0-,.! .+0,+3+5(,/)8! +'2&%7-1! '+5/*&+/+%,! 3&-M*-,58G! ,%5/*&+(G! *&0-,58G! ,*':-&! %3!
+,5%,/+,-,5-!-2+.%1-.G! 3+&./! .-,.(/+%,! /%!7%+1G!(,1!:)(11-&!5(2(5+/8C!R%9-7-&G! .8./-'+5())8!






6(7-! /6-! %2/+%,! %3! (,! %,(:%/*)+,*'/%4+,! J! PaX?XkiQ! +,b-5/+%,! /6(/! +.! (22&%7-1! :8!
S9+..'-1+5! 3%&! /6-! +,1+5(/+%,! %3! +1+%2(/6+5! %7-&(5/+7-! :)(11-&! .+,5-! /6+.! 8-(&C!
X,(:%/*)+,*'/%4+,!J! +.!(!,-*&%/%4+,! /6(/! +.!2&%1*5-1!:8! /6-!(,(-&%:+5!:(5+))*.!B)%./&+1+*'!
:%/*)+,*'C!?6-! 2&-3-&&-1! /82-!J! %3! /6-! /%4+,! .6%9.!(! )%,0-&! 1*&(/+%,! %3! (5/+%,C!a%/*)+,*'!
/%4+,! 2&-7-,/.! /6-! &-)-(.-! %3! J56! (,1! ,-*&%/&(,.'+//-&.! 3&%'! 2&-.8,(2/+5! '*.5)-! 5-)).G!
&-.*)/+,0! +,! (! &-7-&.+:)-! 56-'%E1-,-&7(/+%,! %3! /6-! 1-/&*.%&! '*.5)-C! ?6-! -33-5/! %3! JB6! %,!
2%./.8,(2/+5!'*.5)-!5-)).! +.! +,6+:+/-1!(,1G!/6-&-3%&-G! /6-!1-/&*.%&!'*.5)-!1%-.!,%/!5%,/&(5/!
;#LU>C! a%/*)+,*'/%4+,! +.! +,b-5/-1! 1+&-5/)8! +,/%! /6-! 1-/&*.%&! '*.5)-! (,1! .6%9-1! +,! -(&)+-&!
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3 ANALYTICAL INVESTIGATIONS 
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3.1 Two new flavonol glycosides and a metabolite profile of 
Bryophyllum pinnatum, a phytotherapeutic used in 
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The preparation of the B. pinnatum MeOH extract, its fractionation (Sephadex LH-20 and 
Diaion HP-20 CC), purification of the constituents using semi-preparative and preparative 
HPLC, structure elucidation by NMR spectroscopy, isolation and identification of 
bufadienolides from B. daigremontianum, detection of bufadienolides in B. pinnatum, writing 





Bryophyllum pinnatum (Lam.) Oken (syn. Kalan-
choe pinnata Pers., Bryophyllum calycinum Salisb.)
is a succulent perennial plant native to Madagas-
car and belongs to the family of Crassulaceae. It is
commonly known as life plant, air plant, love
plant, and Goethe plant. B. pinnatum has been
widely used in traditional medicine, especially in
Madagascar, Indonesia, India, Nigeria, Trinidad
and Tobago where the leaves have been utilized
to treat jaundice [1], skin diseases, urinary prob-
lems, hypertension, and for its cooling properties
in topical use [2–4].
In 1921, B. pinnatum preparations were estab-
lished by Rudolf Steiner as anthroposophical
medicines to treat hysteria [5]. Later, B. pinnatum
was also used in obstetrics and gynaecology as a
tocolytic agent to prevent premature labour [6]
and, more recently, to treat sleep disorders in
pregnancy. As a tocolytic agent B. pinnatum
showed only mild and few adverse effects and
was very well tolerated [7]. We could show that
the leaf juice inhibits an oxytocin-induced in-
crease of intracellular calcium concentration in
human myometrial cells [8] and induces myome-
trial relaxation in vitro [9]. Recently, we reported
that B. pinnatum leaf press juice also inhibits por-
cine detrusor contractility in vitro [10]. To explore
the potential of B. pinnatum as a treatment for pa-
tients suffering from overactive bladder syn-
drome, a pilot study in humans was performed. A
positive trend for a B. pinnatum preparation com-
pared to placebo could be shown [11].
Abstract
!
Bryophyllum pinnatum is a succulent perennial
plant native to Madagascar which is used in
anthroposophical medicine to treat psychiatric
disorders and as a tocolytic agent to prevent pre-
mature labour. We performed a metabolite profil-
ing study in order to obtain a comprehensive pic-
ture of the constituents in B. pinnatum leaves and
to identify chromatographic markers for quality
control and safety assessment of medicinal prepa-
rations. Preliminary HPLC‑PDA-ESIMS analyses
revealed that flavonoid glycosides were the main
UV-absorbing constituents in the MeOH extract
of B. pinnatum. Two phenolic glucosides, syringic
acid β-D-glucopyranosyl ester (1) and 4′-O-β-D-
glucopyranosyl-cis-p-coumaric acid (2), as well as
nine flavonoids (3-11) including kaempferol,
quercetin, myricetin, acacetin, and diosmetin gly-
cosides were unambiguously identified by 1H and
2DNMR analysis after isolation from a MeOH ex-
tract. The flavonol glycosides quercetin 3-O-α-L-
arabinopyranosyl-(1→ 2)-α-L-rhamnopyranoside
7-O-β-D-glucopyranoside (3) and myricetin 3-O-
α-L-arabinopyranosyl-(1→ 2)-α-L-rhamnopyran-
oside (4) were new natural products. With the aid
of HPLC‑PDA-APCIMS and authentic references
isolated from the related species B. daigremontia-
num, the presence of four bufadienolides, bersal-
degenin-1-acetate (12), bryophyllin A (13), bersal-
degenin-3-acetate (14), and bersaldegenin-1,3,5-
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With respect to pharmacological properties of B. pinnatum, anti-
leishmanial [12], antiulcer [13], antibacterial [14,15], antitumour
promoting [16], immunosuppressive [17], and antihypertensive
effects [18] have been reported. Compounds identified in the
plant include flavonoids, triterpenes, phytosterols, bufadieno-
lides, fatty acids, and minerals [19]. The flavonoid fraction was
found to consist mainly of kaempferol and quercetin glycosides,
some of which have shown in vitro antileishmanial activity [12,
20]. A series of bufadienolides such as bryophyllins A–C, and ber-
saldegenin derivatives have been isolated [19,21]. These com-
pounds reportedly possess sedative and positive inotropic prop-
erties, as well as CNS-related activities [22]. For safety assessment
and quality control of phytomedicines containing B. pinnatum,
detailed information on their metabolite profile is required.
There have been only a few relevant analytical studies on B. pin-
natum. Four flavonoids were assigned in the HPLC‑UV‑MS chro-
matogram of an aqueous extract [23]. A series of flavonoids were
also identified by HPLC‑UV in a chromatographic fraction [24].
No study includes, however, a comprehensive analysis of the con-
stituents of the plant. We therefore conducted a metabolite
profiling of the MeOH extract in order to identify useful chroma-
tographic markers for quality control and safety assessment,




To obtain a comprehensive metabolite profile, leaves of B. pinna-
tum were extracted with MeOH, and the extract was submitted
to HPLC‑PDA-ESIMS analysis (l" Fig. 1). The UV trace and PDA
spectra revealed the presence of several peaks of UV-absorbing
phenolic compounds. In addition, a group of large peaks eluting
between 19 and 24min were detected in the MS trace. By com-
parison with reference compounds previously isolated by the au-
thors from Lycium barbarum (unpublished results), two peaks at
tR 22.0min (m/z 520.6 [M]+) and tR 23.2min (m/z 496.6 [M]+)
were assigned to linoleoyl lysophosphatidylcholine, and palmito-
yl lysophosphatidylcholine, respectively. In addition, a peak at
tR 20.4min (m/z 518.6) was tentatively assigned to α-linolenoyl
lysophosphatidylcholine. Most peaks detected in the UV trace
could be identified after targeted purification by a combination
of Sephadex LH-20 and Diaion HP-20 column chromatography,
and preparative and semipreparative HPLC. The structures were
established on the basis of UV, 1H and 13C NMR spectra, and by
comparison with literature data.
Compounds 1 (m/z 743.2 [2M + H]+) and 2 (m/z 651.2 [2M – H]−,
325.2 [M – H]−) were shown to be phenolic acid derivatives. They
were identified as syringic acid β-D-glucopyranosyl ester (1) [25]
and 4′-O-β-D-glucopyranosyl-cis-p-coumaric acid (2) [26]. The
cis-configuration of the olefinic double bond in 2 is supported
by the 3JHH-coupling constant of the corresponding protons (H-2
δH 5.85 ppm, H-3 δH 6.53 ppm, J = 12Hz).
Compounds 3-11 exhibited UV spectra characteristic for flavo-
noids. Their structures (l" Fig. 2) were assigned by ESIMS, NMR,
and by comparison with literature data. Compounds 6 (m/z
581.3 [M + H]+, 449.2 [(M + H) – 132]+, 303.2 [(M + H) – 132–
146]+) and 8 (m/z 449.2 [M + H]+, 303.2 [(M + H) – 146]+) were
quercetin glycosides. They were identified as quercetin 3-O-α-L-
arabinopyranosyl-(1→ 2)-α-L-rhamnopyranoside (6) [12], and
quercitrin (quercetin 3-O-α-L-rhamnopyranoside, 8) [20], re-
spectively. Compound 5 (m/z 465.1 [M + H]+, 319.2 [(M + H) –
146]+) was identified as myricitrin (myricetin 3-O-α-L-rhamno-
pyranoside, 5) [27]. Compounds 9 (m/z 565.3 [M + H]+, 433.2 [(M
+ H) – 132]+, 287.2 [(M + H) – 132–146]+) and 10 (m/z 565.3 [M +
H]+, 433.2 [(M + H) – 132]+, 287.2 [(M + H) – 132–146]+) were
shown to be kaempferol glycosides, namely kaempferol 3-O-α-
L-arabinopyranosyl-(1→ 2)-α-L-rhamnopyranoside (9) [12] and
kaempferol 3-O-β-D-xylopyranosyl-(1→ 2)-α-L-rhamnopyrano-
side (10) [28], respectively. Compounds 7 (m/z 609.4 [M + H]+)
and 11 (m/z 593.4 [M + H]+) were identified as diosmine (diosme-
tin 7-O-α-L-rhamnopyranosyl-(1→ 6)-β-D-glucopyranoside, 7)
[29] and acacetin 7-O-α-L-rhamnopyranosyl-(1→ 6)-β-D-gluco-
pyranoside (11) [30], respectively. The positions of the sugar res-
idues and the interglycosidic linkages in all compounds were
supported by HMBC correlations. 1H and 13C NMR data are pro-
vided as Supporting Information.
Compounds 3 and 4 are new flavonol glycosides. Their structures
were established as follows: The HRESIMS spectrum of 3 showed
a quasimolecular [M + Na]+ ion peak at m/z 765.1844, in agree-
ment with amolecular formula of C32H38O20. Fragment ions were
detected atm/z 611.3 [(M + H) – 132]+ and 465.2 [(M + H) – 132–
146]+. The aglycone was identified as quercetin from its NMR da-
ta (l" Table 1) and by comparison with compounds 6 and 8. Acid
hydrolysis afforded D-glucose, L-rhamnose, and L-arabinose. The
monosaccharides were identified by GC‑MS analysis after deriva-
Fig. 1 HPLC‑PDA-ESIMS of the MeOH extract of B.
pinnatum. Top: UV trace (220–400 nm). Bottom:
ESIMS base peak chromatogram (positive ion
mode, m/z 200–1500). SunFire™ C18 column, A:
0.1% aqueous formic acid and B: MeCN, 5–100% B
in A in 30min, 0.5mL/min.
Numbers refer to the isolated compounds 1-11.
Letters refer to α-linolenoyl lysophosphatidylcho-
line (a, tentative assignment), linoleoyl lysophos-
phatidylcholine and an isomer (b, c), and palmitoyl
lysophosphatidylcholine (d), respectively. Peaks at
Rt 19.5 and 20.0min (bothm/z 699.7), 22.6min
(m/z 537.6) and 22.7 (m/z 677.7) could not be
identified. The front peak in the UV trace contains a
large amount of malic acid, as revealed by 1H NMR
analysis.
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tisationwith L-cysteine methyl ester and silylation. The α-config-
uration of the arabinopyranosyl and the β-configuration of the
glucopyranosyl residues were derived from the coupling con-
stant of the anomeric protons at δH 4.16 (d, 5.9 Hz, H-1′′′) and δH
5.06 ppm (d, 6.9 Hz, H-1′′′′), respectively. The α-configuration of
the rhamnopyranosyl residue was assigned by 13C NMR [12].
The NMR data of the disaccharide moiety were in full agreement
with those recorded for compound 6. The interglycosidic linkage
was confirmed by an HMBC correlation between H-1′′′ (δH
4.16 ppm) of the α-L-arabinopyranosyl moiety and C-2′′ (δC
80.1) of the α-L-rhamnopyranosyl residue. The HMBC correlation
between H-1′′ of the rhamnosyl moiety (δH 5.36) and C-3 of the
aglycone (δC 135.0) revealed the attachment of the disaccharide
moiety. The attachment of the β-D-glucopyranosyl moiety at C-7
was established by NOESY contacts of the anomeric proton H-1′′′′
with H-6 and H-8. The structure of 3 was thus established as
quercetin 3-O-α-L-arabinopyranosyl-(1→ 2)-α-L-rhamnopy-
ranoside 7-O-β-D-glucopyranoside.
A molecular formula of C26H28O16 for compound 4 was estab-
lished by HRESIMS spectroscopy ([M + Na]+ quasimolecular ion
at m/z 619.1290). Fragment ions were observed at m/z 465.2 [(M
+ H) – 132]+ and 319.2 [(M + H) – 132–146]+ in the ESIMS spec-
trum. The NMR data (l" Table 2) of the disaccharide moiety were
almost identical with those of compounds 3 and 6. An HMBC cor-
relation between H-1′′ of rhamnose (δH 5.23) and C-3 of the agly-
cone (δC 135.0) indicated the attachment of the sugar moiety.
Table 1 1H and 13C NMR data of compound 3 in DMSO-d6.
Position δH (m, J in Hz) δCb,c Positiona δH (m, J in Hz) δCb
Aglycone Rha
2 – n.d. 1‘‘ 5.36 (s) 100.9
3 – 135.0 2‘‘ 4.06 (s) 80.1
4 – n.d. 3‘‘ 3.63 (m) 70.3
5 – n.d. 4‘‘ 3.16 (m) 72.2
6 6.43 (s) 99.8 5‘‘ 3.63 (m) 70.3
7 – n.d. 6‘‘ 0.93 (d, 5.8) 18.0
8 6.72 (s) 95.0
9 – n.d. Ara
10 – n.d. 1‘‘‘ 4.16 (d, 5.9) 106.2
1‘ – n.d. 2‘‘‘ 3.36 (m) 71.1
2‘ 7.37 (s) 115.9 3‘‘‘ 3.32 (m) 72.6
3‘ – 164.0 4‘‘‘ 3.58 (br s) 67.8
4‘ – 150.4 5‘‘‘ 3.51 (m), 3.29 (m) 65.8
5‘ 6.89 (d, 7.7) 116.2
6‘ 7.29 (d, 7.7) 121.4 Glc
1‘‘‘‘ 5.06 (d, 6.9) 100.6
2‘‘‘‘ 3.28 (m) 73.3
3‘‘‘‘ 3.33 (m) 76.5
4‘‘‘‘ 3.20 (m) 69.8
5‘‘‘‘ 3.44 (m) 77.3
6‘‘‘‘ 3.72 (d, 11.5), 3.48 (m) 60.8
a Rha = α-L-rhamnopyranosyl; Ara = α-L-arabinopyranosyl; Glc = β-D-glucopyranosyl; b 13C NMR shifts derived from HSQC and HMBC data; c n.d. = not detected
Fig. 2 Structures of compounds isolated from
B. pinnatum.
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Compound 4 differed from 6 only in the substitution of the B-
ring. A signal corresponding to two protons appeared as a singu-
let at δH 6.93 ppm. The NMR data of the aglycone were in full
agreement with those of compound 5, confirming the aglycone
to be myricetin. Compound 4 was thus myricetin 3-O-α-L-arabi-
nopyranosyl-(1→ 2)-α-L-rhamnopyranoside. Among the isolated
compounds, only the quercetin glycosides 6 and 8, as well as the
kaempferol glycoside 9were previously identified in B. pinnatum
[12].
Occurrence of bufadienolides in B. pinnatum has been reported
[31], but we could not detect them by HPLC‑PDA-ESIMS analysis
of the MeOH extract. For targeted chromatographic detection,
reference compounds were isolated from a related species, B. dai-
gremontianum, known to contain higher concentrations of bufa-
dienolides. Compounds 12-15 were obtained from the CH2Cl2-
soluble fraction of the MeOH extract by a combination of prepar-
ative and semipreparative HPLC on RP-18. They were identified
as bersaldegenin-1-acetate (12, m/z 475.4 [M + H]+) [22], bryo-
phyllin A (13, m/z 473.4 [M + H]+) [32], bersaldegenin-3-acetate
(14, m/z 475.5 [M + H]+) [22], and bersaldegenin-1,3,5-orthoace-
tate (15, m/z 457.3 [M + H]+) [22] by APCIMS, 1H and 2DNMR. 1H
and 13C NMR data of 12-15 are provided as Supporting Informa-
tion, and their structures are shown in l" Fig. 3.
Using the reference compounds 12–15 isolated from B. daigre-
montianum, the presence of bufadienolides in B. pinnatum was
confirmed by HPLC-APCIMS. The four bufadienolides 12-15 could
be detected in the CH2Cl2-soluble fraction of the MeOH extract of
B. pinnatum (l" Fig. 4). To the best of our knowledge, bersaldege-
nin-1-acetate (12) had not been previously reported as a constit-
uent of B. pinnatum, while compounds 13-15 were already de-
scribed [33]. It is noteworthy that bufadienolides 12-15 could
not be detected by HPLC-ESIMS in the positive or negative ion
mode under these conditions.
In conclusion, our study provides a detailed metabolite profile of
the leaves of B. pinnatum. Two phenolic acids, several flavonol
and O-methylated flavone glycosides, a bufadienolide, and lyso-
phosphatidylcholine derivatives were identified for the first time
in this plant which is currently the object of clinical investiga-
Table 2 1H and 13C NMR data of compound 4 in DMSO-d6.
Position δH (m, J in Hz) δC b,c Positiona δH (m, J in Hz) δCb
Aglycone Rha
2 – 157.4 1‘‘ 5.23 (br s) 101.5
3 – 135.0 2‘‘ 4.06 (br s) 80.8
4 – n.d. 3‘‘ 3.66 (dd, 9.3, 3.2) 70.8
5 – 162.0 4‘‘ 3.15 (dd, 9.5, 9.4) 72.4
6 6.22 (s) 97.6 5‘‘ 3.81 (dq, 10.0, 6.4) 70.7
7 – 164.8 6‘‘ 0.95 (d, 6.4) 17.8
8 6.42 (s) 92.5
9 – 156.8 Ara
10 – 104.3 1‘‘‘ 4.09 (d, 6.7) 106.9
1‘ – 119.9 2‘‘‘ 3.31 (dd, 8.9, 6.7) 71.6
2‘ 6.93 (s) 107.9 3‘‘‘ 3.29 (dd, 9.0, 2.9) 73.0
3‘ – 146.5 4‘‘‘ 3.55 (br s) 68.1
4‘ – 137.9 5‘‘‘ 3.44 (dd, 12.0, 2.0), 3.23 (br d, 12.0) 66.2
5‘ – 146.5
6‘ 6.93 (s) 107.9
a Rha = α-L-rhamnopyranosyl, Ara = α-L-arabinopyranosyl; b 13C NMR shifts derived from HSQC and HMBC data; c n.d. = not detected
Fig. 3 Structures of bufadienolides isolated from B. daigremontianum and
detected in B. pinnatum.
Fig. 4 Presence of bufadienolides in the CH2Cl2 soluble fraction of B. pin-
natum: HPLC-APCIMS base peak chromatogram (positive ion mode, m/z
150–1500). SunFire™ C18 column, A: 0.1% aqueous formic acid and B:
MeCN, 5–100% B in A in 30min, 0.5mL/min. Numbers refer to bufadieno-
lides 12-15. * This peak (m/z 475.3) was tentatively assigned to bryophyllin
C [34]. Peaks at Rt 11.0min (m/z 197.2) and Rt 11.3min (m/z 477.3, 459.3)
were not identified.
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tions in different therapeutic indications [10,11]. Two flavonol
glycosides were new natural products. Most peaks detected by
HPLC‑PDA-ESIMS could be structurally assigned. In addition, bu-
fadienolides could be unambiguously detected by HPLC-APCIMS.
In agreement with previous reports, flavonoids are the main UV-
active constituents of the MeOH leaf extract. The major peak was
found to be quercetin 3-O-α-L-arabinopyranosyl-(1→ 2)-α-L-
rhamnopyranoside (6), confirming a previous report of its occur-
rence as the main flavonoid in an aqueous extract [23]. The flavo-
noids identified are suited as chemical markers for quality con-
trol of medicinal preparations, whereas the bufadienolides are
important for safety assessment regarding the presence or ab-




Solvents were from Scharlau. Technical grade solvents were used
after redistillation for extraction and CC. HPLC grade solvents
were used for HPLC. HPLC grade water was obtained by an
EASY-pure II (Barnstead) water purification system. Diaion HP-
20 (250 µm) was purchased from Supelco. Sephadex LH-20 was
obtained from Pharmacia Fine Chemicals. A pump (model 881;
Büchi) and a fraction collector (Superfrac; Pharmacia Biotech)
were used for CC on Sephadex LH-20. For TLC analysis, silica gel
plates F254 (10–12 µm; Merck) were used with MeOH/EtOAc
(1:3) or CHCl3/MeOH/H2O (65:35:5) as the mobile phase.
Detection was at UV 254 and 366 nm, and after staining with va-
nillin/sulfuric acid reagent or Natural Product Reagent A (1%
ethanolamine diphenylborate; Sigma-Aldrich). Silica gel plates
60F264 s (5–6 µm; Merck) were used for HPTLC with EtOAc/
HCOOH/AcOH/H2O (100:11:11:26) as the mobile phase. Detec-
tion was at 366 nm after spraying with Natural Product Reagent
A. GC‑MS analysis was performed using an HP 5890 Series II gas
chromatograph equipped with an HP 5971 mass selective detec-
tor (Hewlett Packard). HPLC‑PDA‑MS analyses were performed
using an Agilent 1100 Series HPLC coupled to a Bruker Esquire
3000 plus mass spectrometer. Separations were performed on a
C18 SunFire™ column (3.5 µm, 3 × 150mm; Waters) equipped
with a guard column (3 × 10mm). The samples were dissolved in
DMSO at a concentration of 3mg/mL (extract, fractions) or
0.6mg/mL (pure compounds). 10 µL (fractions, compounds) or
20 µL (extract) were injected. The mobile phase consisted of
0.1% aqueous formic acid (A) and MeCN (B), and a linear gradient
of 5–100% B in 30minwas applied. The flow ratewas 0.5mL/min.
UV spectra were recorded from 210 to 400 nm. ESIMS spectra
were obtained in positive and negative ion modes between m/z
200 and 1500. APCIMS spectra were recorded in the positive ion
mode betweenm/z 150 and 1500. Semipreparative HPLCwas car-
ried out on an Agilent 1100 Series system connected to a PDA de-
tector. Separations were performed on a Waters SunFire™ C18
column (5 µm, 10 × 150mm) equipped with a precolumn (5 µm,
10 × 10mm). The mobile phase consisted of 0.1% aqueous formic
acid (A) and MeCN (B). The flow rate was 3mL/min. Preparative
HPLCwas performed on a Shimadzu LC-8A instrument connected
to a SPD-M10AVP PDA detector. A Waters SunFire™ C18 OBD™
column (5 µm, 30 × 150mm) was used for separation. The mobile
phase consisted of 0.1% aqueous formic acid (A) and MeCN (B).
The flow rate was 20mL/min. 1H NMR and 2DNMR (COSY, HSQC,
HMBC, selective TOCSY, HSQC-TOCSY) data were recorded in
DMSO-d6 or in CDCl3 on a Bruker Avance III™ 500MHz NMR
spectrometer equipped with a 1-mm TXI microprobe. Data were
processed with Topspin 2.1 software (Bruker). Optical rotation
was measured on a Perkin Elmer Model 341 polarimeter. UV
spectra of 3 and 4 were recorded on a Lambda 35 spectropho-
tometer (Perkin Elmer). HRESIMS data were obtained on a Mi-
crOTOF mass spectrometer (Bruker Daltonics).
Plant material
Bryophyllum pinnatum leaves were harvested from plants culti-
vated in Schwäbisch Gmünd, Germany, by Weleda Schwäbisch
Gmünd, Germany, in July and August 2010. A voucher specimen
(ZSS 29715) has been deposited at The Zurich Succulent Plant
Collection. Bryophyllum daigremontianum leaves were harvested
from plants grown in Arlesheim, Switzerland by Ita Wegman
Hospital Arlesheim, Switzerland in September 2011. A voucher
specimen (838) has been deposited at the Division of Pharmaceu-
tical Biology, University of Basel. After harvesting, the leaveswere
frozen and stored at − 20°C until processing.
Extraction
The frozen leaves of B. pinnatum and B. daigremontianum were
lyophilized. The dried leaves were pulverised in a mortar, and
the powder (B. pinnatum: 593.4 g, B. daigremontianum: 37.5 g)
was extractedwithMeOH (B. pinnatum: 6 L, B. daigremontianum:
400mL). The suspension was stirred for 2 h and subsequently so-
nicated for an additional 20min. The extract was filtred and
evaporated under reduced pressure to yield the MeOH extract
(B. pinnatum: 53.4 g; B. daigremontianum: 7.1 g).
Fractionation of B. pinnatum leaf extract
A portion of the MeOH extract (9.0 g) was dissolved in 20mL of
MeOH, applied to a Sephadex LH-20 column (5.5 × 100 cm i.d.)
and elutedwithMeOH at a flow rate of 2mL/min. 9-Min fractions
were collected and combined based on TLC analysis to afford 10
main fractions: B1 (Fr. 1–51, 0.04 g), B2 (Fr. 52–67, 0.38 g), B3 (Fr.
68–79, 2.68 g), B4 (Fr. 80–97, 2.23 g), B5 (Fr. 98–110, 0.17 g), B6
(Fr. 111–123, 0.42 g), B7 (Fr. 124–146, 0.16 g), B8 (Fr. 147–165,
0.33 g), B9 (Fr. 166–196, 0.05 g), and B10 (Fr. 197–241, 0.35 g).
Based on HPTLC and HPLC‑UV-ESIMS analyses, fractions B4, B6,
and B8 were selected for further investigation. Fraction B4
(2.21 g) was separated by CC (2.5 × 41 cm i.d.) on Diaion HP-20.
The sample was dissolved in H2O, and the column eluted succes-
sively with 750mL of H2O and 1 L of MeOH. An aliquot (610mg)
of the MeOH fraction eluted from fraction B4 was separated by
preparative HPLC using a linear gradient of 5–45% B in 30min.
The sample dissolved in DMSO (1 g/mL) was injected as 6 aliquots
to provide compounds 1 (3.6mg, tR 11.5min), 11 (5.5mg,
tR 25.0min), and a mixture (3.4mg, tR 13.6min) which was fur-
ther separated by semi-preparative HPLC with a linear gradient
of 10–30% B in 30min to provide compounds 2 (0.9mg,
tR 10.7min) and 3 (1.1mg, tR 11.4min). A second aliquot
(506mg) of the same fraction was separated by semipreparative
HPLC with a linear gradient of 10–45% B in 30min. The sample
dissolved in 1mL DMSOwas injected in 11 portions to yield com-
pound 7 (4.9mg, tR 14.3min). Fraction B6 (390mg) was sepa-
rated by preparative HPLC with a linear gradient of 20–50% B for
30min. The sample dissolved in DMSO (125mg/mL) was injected
as 3 aliquots to give compounds 4 (2.4mg, tR 8.2min), 6 (71.6mg,
tR 10.0min), 9 (11.0mg, tR 12.0min), and 10 (1.0mg, tR 12.6min).
Fraction B8 (430mg) was separated by preparative HPLC as 3 ali-
quots using the same system to result in compounds 5 (5.1mg,
tR 9.0min) and 8 (2.1mg, tR 11.4min).
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side 7-O-β‑D-glucopyranoside (3): yellow amorphous powder.
UV (MeOH): λmax (log ε): 207 (4.55), 256 (4.27), 268 (4.16), 350
(4.03); [α]D – 94 (c 0.044, MeOH); 1H and 13C NMR data
(DMSO‑d6): see l" Table 1. HRESIMS: m/z 765.1844 [M + Na]+
(calcd. for C32H38NaO20: 765.1849); ESIMS: m/z 743.2 [M + H]+,
611.3 [(M + H) – 132]+, 465.2 [(M + H) – 132–146]+.
Myricetin 3-O-α‑L-arabinopyranosyl-(1→ 2)-α‑L-rhamnopyrano-
side (4): yellow amorphous powder. UV (MeOH): λmax (log ε):
209 (4.41), 258 (3.92), 303 (sh, 3.55), 353 (3.81); [α]D – 72 (c
0.069 MeOH); 1H and 13C NMR data (DMSO‑d6): see l" Table 2.
HRESIMS: m/z 619.1290 [M + Na]+ (calcd. for C26H28NaO16:
619.1270); ESIMS: m/z 597.1 [M + H]+, 465.2 [(M + H) – 132]+,
319.2 [(M + H) – 132–146]+.
Acid hydrolysis and sugar analysis
Compound 3 (0.5mg) was heated at 100°C in 2N HCl (1mL) for
2 h. After cooling, the mixture was extracted with EtOAc
(2 × 0.5mL), and the aqueous phase freeze-dried. The sugars were
redissolved in anhydrous pyridine, derivatised with L-cysteine
methyl ester hydrochloride (200 µL, 60°C, 1 h) and subsequently
silylated with hexamethyldisilazane and chlorotrimethylsilane
(Fluka) in pyridine (2:1 :10; 300 µL; 60°C, 30min). GC‑MS anal-
ysis was performed on a DB-225MS column (0.25 µm;
0.25mm × 30m; Agilent). The oven temperature was initially
held 2min at 150°C, then increased to 270°C at a rate of 5°C/
min, and finally kept at 240°C for 10min. The injector tempera-
ture was 300°C and the transfer line temperature 280°C. The He
pressure was 0.8 bar and the splitting ratio 1:10. L-arabinose (tR
13.93min), L-rhamnose (tR 14.62min), and D-glucose (tR
16.23min) were identified by comparison with reference sugars
treated under the same conditions.
Isolation of bufadienolides
A portion (4.0 g) of the MeOH extract of B. daigremontianumwas
partitioned between CH2Cl2 and H2O. The CH2Cl2 soluble fraction
(0.9 g) was shown by HPLC‑PDA-APCIMS analysis to contain the
bufadienolides and was separated by preparative HPLC using a
linear gradient of 5–100% B for 30min. The sample was dissolved
in 4.4mL DMSO and injected as 11 aliquots. Compounds 12
(2.2mg, tR 13.3min) and 15 (4.1mg, tR 17.8min), and a bufadie-
nolide mixture (1.5mg, tR 13.9min) were obtained. The latter
was further separated by semipreparative HPLC using a linear
gradient of 10–80% B in 30min. Compounds 13 (0.7mg,
tR 13.9min) and 14 (0.8mg, tR 14.2min) were obtained.
Detection of bufadienolides in B. pinnatum
A portion of the MeOH extract (1.0 g) of B. pinnatum was parti-
tioned between CH2Cl2 and H2O. The CH2Cl2 soluble fraction
(80mg) was analysed by HPLC‑PDA-APCIMS. The sample was dis-
solved in DMSO (1mg/mL), and 20 µL was injected. Analysis was
performedwith a linear gradient of 5–100% B in 30min, at a flow
rate of 0.5mL/min. Bufadienolides 12-15were identified by com-
parison with reference compounds isolated from B. daigremon-
tianum.
Supporting information
1H NMR spectra of 3 and 4, as well as 1H and 13C NMR data of com-
pounds 1, 2, and 5–15 are provided as Supporting Information.
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S! O! "PGVG Pcc! NVbP!^=7!PVN_! "SVd
b! PVDb!^&_! dDVb ! ! !
d! O! "KPVb ! ! !
"N! O! "NGV" ! ! !
"c! O! ">NVD ! ! !
>c! PVd"!^&_! "NbVd ! ! !
Dc! O! "GPVD ! ! !
Gc! O! "DPVb ! ! !
Kc! O! "GPVD  ! !






































8'&$2$'(! įA^.7!%!$(!A<_! įE@_7/_ 8'&$2$'(,_! įA^.7!%!$(!A<_! įE@_
&'()*+,-! ! /01! !! !
>! O! "KSV" "cc! KVDG!^@-!&_! "N"VG
D! O! "DGVb >cc! GVNK!^@-!&_! bNVb
G! O! (V=V Dcc! DVP"!^._! SNVP
K! O! "P"VS Gcc! DV"S!^==7!dVG7!dVK_! S>VD
P! PV>"!^&_! ddVN Kcc! DVP"!^._! SNVP
S! O! "PGVP Pcc! NVd>!^=7!PVN_! "SVb
b! PVDd!^&_! dGVN ! !
d! O! "KPV> &21! !
"N! O! "NGVN "ccc! GV"G!^=7!PVd_! "NPVP
"c! O! ">"VN >ccc! DVDP!^._! S"VS
>c! SVDK!^&_! ""PV> Dccc! DVDD!^._! S>Vb
Dc! O! "GKVd Gccc! DVKb!^._! PbVD
Gc! O! "GdVD Kccc! DVKN^._7!DV>S^=7!""VS_! PPV>
Kc! PVdd!^=7!bV"_! ""PV>  ! !








































8'&$2$'(! įA!^.7!%!$(!A<_! įE@_ 8'&$2$'(,_! įA!^.7!%!$(!A<_! įE@_
&'()*+,-! ! .(*! !
>! O! "PGVK "cc! KVNb!^=7!PVb_! "NNVG
D! PVSS!^&_! "NGV> >cc! DVP"!^._! SPV"
G! O! "b"Vb Dcc! DV"d!^._! SNV"
K! O! "P>VD Gcc! DVD"!^._! SDVP
P! PVGS^&_! "NNV" Kcc! DVDK!^._! SPVb
S! O! "PDV> Pcc! DVbb!^._7DVGd!^._! PPVK
b! PVSS^&_! dKV> ! !
d! O! "KSVP /01! !
"N! O! "NKVb "ccc! GVKd!^@-!&_! "NNVb
"c! O! ">DVG >ccc! DVSN!^._! SNVS
>c! SVGK!^&_! ""DVP Dccc! DVKN!^._! S"V>
Dc! O! "GSV> Gccc! DV"b!^._! S>VP
Gc! O! "K"Vb Kccc! DVGK!^._! PbVS
Kc! SV">!^=7!bVD_! "">Vb Pccc! "VNd!^=7!KVS_! "bVD
Pc! SVKG!^=7!bVD_! ""dVD  !
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&'()*+,-! !! ! /01! !! !
>! O! "KSVb "cc! KV>b!^@-!&_! "N>VD
D! O! "DGVd >cc! DVdd!^@-!._! SNVK
G! O! (V=V Dcc! DVKD!^==7!>Vb7!dV"_! SNVd
K! O! "P"VP Gcc! DV"S!^==7!dV"7!dVD_! S"VS
P! PV>"!^&_! ddVN Kcc! DV>K!^=h7!PV>7!dV"_! SNVd
S! O! "PGVK Pcc! NVbG!^=7!PVN_! "bVN
b! PVDd!^&_! dGV"  ! !
d! O! "KPVK  ! !
"N! O! "NGVP  ! !
"c! O! ">"V>  ! !
>c! SVD"!^&_! ""PV"  ! !
Dc! O! "GKVS  ! !
Gc! O! "GbVP  ! !
Kc! PVbb!^=7!bVD_! ""KVd  ! !






































8'&$2$'(! įA!^.7!%!$(!A<_! įE@_7/_ 8'&$2$'(,_! įA!^.7!%!$(!A<_! įE@_
&'()*+,-! ! /01! !! !
>! O! "KSVD "cc! KVG>!^@-!&_! "N"V>
D! O! "DGVS >cc! GVND!^@-!._! bNVK
G! O! (V=V Dcc! DVKS!^._! SNVb
K! O! "P"VS Gcc! DV"K!^==7!dVK7!dVK_! S>V>
P! PV>N^=7!"Vb_! ddV" Kcc! DVG>!^=h7!PVD7!dVK_! SNVb
S! O! "PKV" Pcc! NVbd!^=7!PV>_! "SVd
b! PVDd^=7!"Vb_! dGV> ! !
d! O! "KPVG &21! !
"N! O! "NGVG "ccc! GV>N!^=7!PVG_! "NPVK
"c! O! ">NVb >ccc! DVDS!^._! S"VP
>c! SVSP!^=7!bVP_! "DNVS Dccc! DVDK!^._! S>Vd
Dc! PVdD!^=7!bVS_! ""PVG Gccc! DVKS!^._! PbVN
Gc! O! "PNV" Kccc! DVKP!^._7!DVDN!^=7!""7b_! PPV"
Kc! PVdD!^=7!bVS_! ""PVG  !
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>! O! "KSVD! "cc! KVDd!^@-!&_! "N"V>
D! O! "DGVS! >cc! GVN"!^@-!._! bNVb
G! O! (V=V! Dcc! DVKS!^==7!GV"7!dVD_! SNVS
K! O! (V=V! Gcc! DV"G!^==7!dVG7!dVG_! S>V>
P! PV"P!^&_! ddVS! Kcc! DVG>!^=h7!PVG7!"NV>_! SNVS
S! O! (V=V! Pcc! NVbd!^=7!PV"_! "SVb
b! PVDK!^&_! dGVG! ! !
d! O! (V=V! 3)(! !
"N! O! "NGV"! "ccc! GV>"!^=7!SVK_! "NPVP
"c! O! ">NVD! >ccc! DV">!^==7!bVb7!bVb_! SPVP
>c! SVSK!^=7!bVK_! "DNVS! Dccc! >Vdd!^==7!bVD7!bVG_! SGV"
Dc! PVdD!^=7!bVK_! ""KVd! Gccc! DV>K!^==7!GVS7!bVD_! PdVb
Gc! O! "PNVP! Kccc! DVKS!^==7!KV"7!""VS_7!>VdS!^@-!=7!""VD_! PPV>
Kc! PVdD!^=7!bVK_! ""KVd!  !


































8'&$2$'(! įA^.7!%!$(!A<_! įE@_ ! 8'&$2$'(,_! įA^.7!%!$(!A<_! įE@_
&'()*+,-! ! ! .(*! !
>! O! "PGVK ! "cc! KVNP!^=7!SV"_! "NNVP
D! PVbP!^&_! "NGV> ! >cc! DVP"!^._! SPV>
G! O! "b>VK ! Dcc! DV"d!^._! SNV"
K! O! "P>V" ! Gcc! DVD"!^._! SDVP
P! PVGK!^&_! "NNV> ! Kcc! DVDK!^._! SPVb
S! O! "PDVN ! Pcc! DVbd!^._7!DVGb!^._! PPVK
b! PVSS!^&_! dKV> ! ! !
d! O! "KSVP ! /01! !
"N! O! "NPVN ! "jjj! GVKd!^@-!&_! "NNVd
"c! O! ">DV" ! >jjj! DVSN!^._! SNVb
>c! bVN"!^=7!bVG_! ">bVK ! Djjj! DVKN!^._! S"VD
Dc! SV"D!^=7!bVG_! ""KV" ! Gjjj! DV"b!^._! S>VK
Gc! O! "P>Vb ! Kjjj! DVGK!^._! PbVS
Kc! SV"D!^=7!bVG_! ""KV" ! Pjjj! "V"N!^=7!KVd_! "bV>
Pc! bVN"!^=7!bVG_! ">bVK !  ! !
































8'&$2$'(! įA@_^.7!%!$(!A<_! įE,_7@_ !
"! KVKN!^@-!&_! SNVS !
>! "VdK!^._7!"Vbd!^._! DNVd !
D! GV""!^@-!&_! PKVG !
G! >V>"!^@-!=7!"GVG_7!"VKK!^._! DSV> !
K! O! S>V> !
P! >V">!^._7!"VP>^._! DPV> !
S! "VGP^._7!"V>>!^._! >"Vd !
b! "VGN!^=_! G>VG !
d! "VKG!^@-!=7!"NVd_! G"VG !
"N! O! (V=V !
""! (V=V! (V=V !
">! "VDb!^._7!"V>b^._! DdV> !
"D! O! GbVN !
"G! O! bDVG !
"K! "VdK!^._7!"VKG^=7!"NVd_! D"VS !
"P! >VNN!^._7!"VPN!^._! >bV" !
"S! >VGK!^==7!PVP7!bVD_! KNV> !
"b! NVK"!^&_! "SVN !
"d! "NVNN!^&_! >NPVP !
>N! O! ">>Vd !
>"! SVGd!^&_! "GdVG !
>>! SVbS!^==7!"Vd7!dVb_! "GSVK !
>D! PV>P!^=7!dVd_! ""GVG !
>G! O! "P"VS !
>K! O! "PdVd !



























8'&$2$'(! įA@_^.7!%!$(!A<_! įE,_7@_ !
"! KV"G!^=7!DVD_! S>Vd !
>! >V"K!^._7(V=V! >SVd !
D! GV>K!^@-!&_! PSVD !
G! >VDD!^=7!"DVP_7"VSP^@-=7!"Vb7!"DVD_! DDVP !
K! O! SKV" !
P! >V"d!^===7!GVS7!"DVK7!"DVK_7!"VKN!^._! DDVD !
S! >VNK!^._7!"V>S!^._! >>VD !
b! "VKN!^._! G"VD !
d! "VPG!^._! GPVd !
"N! O! (V= !
""! DVSd!^===7!GVG7!"NVd7!"NVd_! PPV" !
">! "VKP!^._7!"VDN!^._! GdVK !
"D! O! GdV" !
"G! O! b>VK !
"K! >VNN!^._7!"VKb!^._! D"Vb !
"P! >VNb!^._7!"VP"!^._! >bVK !
"S! >VGS!^==7!KVK7!dV"_! KNV> !
"b! NVKK!^&_! "SVS !
"d! "NV"N!^&_! >NSVb !
>N! O! ">>VG !
>"! SVK>!^=7!"VP_! "GdVS !
>>! SVbK!^==7>VP7!dVb_! "GSVK !
>D! PV>P!^=7!dVS_! ""GVG !
>G! O! "P"VS !
>K! O! ""NVN !




























8'&$2$'(! įA^.7!%!$(!A<_! įE,_ !
"! GVGD!^@-!&_! PbVb !
>! >VN"^._7!"VdG^._! D"V" !
D! KVNP^@-!&_! PbVS !
G! "VKd^._7!>VD"^._! DPV" !
K! O! SDV> !
P! >V"K!^===7!GVD7!"DVK7!"DVS_7!"VK"^._! DPV" !
S! >VN>^._7!"V"G^._! >GVD !
b! "VG"^._! G>V> !
d! "VKP^._! G"V" !
"N! O! KPVN !
""! "VG>^._7!"VDK^._! >"VG !
">! "VDG^._7!"V>G^._! DdVP !
"D! O! GbVN !
"G! O! bDV" !
"K! "VdD^._7!"VK"^._! D"Vd !
"P! >VN>^._7!"VKb^._! >bVK !
"S! >VGG^==7!dVG7!KVG_! KNVG !
"b! NVKD!^&_! "SV" !
"d! "NV"N!^&_! >NbVG !
>N! !O! ">>Vd !
>"! SVGd!^=7!"VS_! "GdVG !
>>! SVbb!^==7!>VK7!dVb_! "GSVP !
>D! PV>P!^=7!dVS_! ""GVG !
>G! O! "P"VS !
>K! O! "SNV" !






























8'&$2$'(! įA^.7!%!$(!A<_! įE,_ !
"! GVK"!^@-!&_! SNVP !
>! >VG"!^._7!"VKd^._! >SV> !
D! GV>P!^@-!&_! PPVP !
G! >V"G!^@-!&_7!"Vd"!^._! DDVK !
K! O! SGVG !
P! >V>G!^===7!GV"7!"DVK7!"DVK_7!"VKS!^._! D>VP !
S! >VNK!^._7!"VD>!^._! >>V> !
b! "VKP!^._! G>VK !
d! "VGG!^._! G"V" !
"N! O! K>VP !
""! "VK>!^._7!"V>d!^._! >NVS !
">! "VGG!^._7!"V"d!^._! GNV> !
"D! O! GbVS !
"G! O! bGVN !
"K! "VbG!^._7!"VPD^._! D"VS !
"P! >V"N!^._7!"VPd!^._! >bVD !
"S! >VDb!^._! KNVb !
"b! NVKd!^&_! "PV" !
"d! "NV"N!^&_! >NPVS !
>N! O! ">>VD !
>"! SV"K!^&_! "GbVK !
>>! SVPb!^==7!"VK7!dVd_! "GPVD !
>D! PV"P!^=7!PV>_! ""KV" !
>G! O! "P"VS !
>K! O! ""NVb !



























































































4 PHARMACOLOGICAL EXPERIMENTS 
 111 
4.1 Bryophyllum pinnatum inhibits detrusor contractility in 
porcine bladder strips - A pharmacological study towards a 
new treatment option of overactive bladder 
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The effect of the B. pinnatum leaf press juice on the porcine detrusor contractility was 
demonstrated in vitro. The leaf press juice (10%) produced a maximum relaxation of 18.7% 
on carbachol pre-contracted detrusor contractility and a maximum inhibition of 74.6% in 
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a b s t r a c t
Aims: A broad spectrum of synthetic agents is available for the treatment of overactive bladder. Anti-
cholinergic drugs show a poor compliance due to side effects. There is an increasing use of plant extracts
in medicine. We have therefore investigated the inhibitory effects of leaf press juice from Bryophyllum
pinnatum (Lam.) Oken (Kalanchoe pinnata L.) on bladder strips and compared the effects to that of
oxybutynin.
Methods: Strips of porcine detrusor were prepared in Krebs solution and contractility was measured in a
myograph system chamber airedwith O2/CO2 at 37 ◦C. To induce contractions, electrical field stimulation
(32Hz, 40V) was used for the inhibitory effect measurements, and carbachol (50!M) for the relaxant
effectmeasurements. Recordingswere obtained in the absence andpresence of increasing concentrations
of Bryophyllum pinnatum leaf press juice (BPJ, 0.1–10%), and oxybutynin (10−7–10−3 M) as a reference
substance.
Results: In inhibition experiments, BPJ aswell as oxybutynin inhibited electrically induced contractions of
porcine detrusor. BPJ at concentrations of 5% inhibited the contraction compared to a timematched con-
trol significantly by 74.6±10.2% (p<0.001). BPJ as well as oxybutynin relaxed carbachol pre-contracted
porcine detrusor strips. The maximum relaxant effect of BPJ compared to a time matched control was
18.7±3.7 (p<0.05) at a concentration of 10% BPJ.
Conclusions:Our investigations show that BPJ inhibits contractions induced by electrical field stimulation
and relaxes carbachol-induced contractions. However, the effect was lower than that of the reference
substance oxybutynin. It is important to continue in vitro experiments as well as clinical studies with BPJ
that might offer a new treatment option for patients with OAB.
© 2012 Elsevier GmbH. All rights reserved.
Introduction
Lower urinary tract dysfunction causing urgency with or with-
out urge incontinence, usually accompanied by frequency and
nocturia, was defined by the International Continence Society (ICS)
in 2002 as the overactive bladder (OAB) syndrome (Abrams et al.
∗ Corresponding author at: Department of Obstetrics, Research Perinatal Phar-
macology, University Hospital Path G 51 a, Schmelzbergstrasse 10, CH-8091 Zurich,
Switzerland.
E-mail address: ursula.vonmandach@bluewin.ch (U. von Mandach).
2002). This new term, which replaces older terms such as unstable
bladder/detrusor instability and detrusor hyperreflexia, is a symp-
tomatic diagnosis. The fundamental cause of OAB remains to be
discovered and there is some evidence that myogenic (Brading
1997), aberrant neurogenic activity (DeGroat 1997) and cerebral
alterations (Griffiths et al. 2005) aswell as atypical or latent bladder
infections (Kavia et al. 2005) are involved in its pathogenesis. Invol-
untary detrusor contractions that are of clinical importance and
demonstrable during urodynamic fill cystometry can be simulated
in an in vitromodel of bladder muscle strips.
OAB syndrome affects a considerable part of the population:
Prevalence of OAB is at least as high as the rates of many other
0944-7113/$ – see front matter © 2012 Elsevier GmbH. All rights reserved.
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chronic diseases, including asthma, coronary-artery disease and
peptic-ulcer disease (Chapple et al. 2008). Depending on the
definition for OAB which were used in different epidemiologic
studies, prevalence values range from 11.8% (Irwin et al. 2006) to
16.6% (Milsom et al. 2001). Only Irwin et al. based their multina-
tional, population based, cross-sectional survey on the current ICS
definitions. All of the mentioned studies found similar prevalence
rates of OAB in men  and women, and an increase in prevalence
with older age.
OAB  affects many aspects of daily life, like domestic behaviour,
social interactions, sexuality, work life, physical activities and over-
all psychological well-being. Nevertheless, Milsom et al. revealed
that only a small proportion of affected individuals currently
receive treatment: Only 60% of the interviewed individuals had
spoken to a doctor about their disorders, and among these, 73%
remained without medication.
The management of OAB includes a broad spectrum of treat-
ments, such as behaviour modification, pharmacotherapy, pelvic
floor muscle training, electrostimulation and surgery. Antimus-
carinics, such as oxybutynin, tolterodine, darifenacin, solifenacin,
fesoterodin, and trospium chloride are the only oral drug class
to demonstrate a positive benefit-to-risk ratio. Anticholinergics
remain the first line treatment for OAB (Andersson 2011). How-
ever, the lack of selectivity of antimuscarinics to the muscarinergic
receptors of the bladder muscle and urothelial cells leads to sys-
temic anticholinergic side effects, such as dry mouth, tachycardia,
cognitive problems, constipation and accommodation paralysis
(i.e., blurred vision). These side effects limit the clinical use of this
drug class, especially in the elderly (Andersson 2011). Long-term
compliance in an observational study was low, with less than 20% of
subjects continuing the medication after 6 months (Kelleher et al.
1997). In a recent prospective tolerability and efficacy study, the
compliance of the participants was much higher with 61% after 12
weeks (Herschorn et al. 2010).
For these reasons, interest in novel drug development for a
more effective and well-tolerated treatment of OAB has increased
in recent years. As OAB is a multilevel disease involving bladder,
neuronal and cerebral aspects, a new drug is expected to modulate
all levels in a favourable manner.
Complementary medicine systems like phytotherapy or anthro-
posophic medicine are appreciated by a growing number of
patients and physicians, due to good tolerability and efficacy in var-
ious diseases. Phytomedicines are quite popular in some European
countries where they may  be prescribed by medical doctor, and
fully or partially reimbursed by the health care system.
Bryophyllum pinnatum (Lam.) Oken (B. pinnatum, Crassulaceae)
is a perennial plant originating from Madagascar. The plant is grow-
ing widely in tropical Africa, tropical America, India, China and
Australia, and is known by a multitude of synonyms and common
names like Kalanchoe pinnata Lam., B. calycinum Salisb., life plant,
air plant, love plant, Canterbury bells, Cathedral bells, etc. Its uses in
folk medicine have been as diverse as its names and included appli-
cations as an antimicrobial, antifungal, antiprotozoal, antiulcer,
antiinflammatory, analgesic, sedative, muscle relaxant, antihyper-
tensive and antiallergic (Kamboj and Saluja 2009). In Europe, the
use of remedies prepared from the species B. pinnatum is limited
almost exclusively to anthroposophic medicine where it was intro-
duced by Rudolf Steiner in 1921 for treatment of “hystery” (Hamre
et al. 2006). Since 1970, B. pinnatum is used in anthroposophically
oriented hospitals as routine treatment of preterm labour (Plangger
et al. 2006).
Some phytochemical studies from B. pinnatum have been con-
ducted which led to the identification of bufadienolides (Yamagishi
et al. 1989), flavonoids, flavonoid glycosides (Muzitano et al. 2006),
and several phenolics and organic acids (Muzitano et al. 2006) from
B. pinnatum. However, no pharmacological studies with extracts
nor  isolated compounds have been conducted prior to our investi-
gations (Wächter et al. 2011).
An in vitro study showed that B. pinnatum reduced the con-
tractility of myometrium muscle strips in both spontaneous and
stimulated contractions (Gwehenberger et al. 2004). We  recently
demonstrated a relaxant effect of B. pinnatum leaf press juice
(BPJ) and some chromatographic fractions on myometrium strips
(Gwehenberger et al. 2004).
Encouraged by these findings, we  tested the effect of BPJ on
detrusor contractility in an in vitro porcine bladder model.
Materials and methods
Plant  material
B.  pinnatum plants were provided by Weleda Brazil. A voucher
specimen number ZSS 29717 is deposited at the Zurich Succulent
Plant Collection, Switzerland. The plants (leaves) were harvested
in Brazil (03/15/2010) by Mr.  Moaci Copani, Weleda Brazil, in the
morning before flowering. Thereafter the fresh plant material was
placed in a refrigerated box and immediately sent by airplane to
Weleda Arlesheim, Switzerland. The plants were kept refrigerated
and processed within 3 days of arrival by mechanical pressing in
a roller mill to obtain BPJ (Weleda 03/23/2010). The procedure
corresponded to the production process for the active ingredient
of Weleda. Bryophyllum 50% tablets (Weleda AG, Arlesheim). The
juice was stored in aliquots of 1.5 ml  at −80 ◦C.
Chemicals and solutions
Carbamyolinecholine chloride (carbachol) and oxybutynin chlo-
ride were purchased from Sigma–Aldrich (Schnelldorf, Germany).
The  Krebs solution contained (in mmol/l): 119 NaCl
(AppliChem,) 15.0 NaHCO3 (Merck, Darmstadt, Germany), 4.6
KCl (Haenseler AG, Herisau, Switzerland), 1.5 CaCl2 (Merck,
Darmstadt, Germany), 11.0 Glucose (Sigma–Aldrich, Steinheim,
Germany), 1.2 MgCl2× 6 H2O (Merck, Darmstadt, Germany), 1.2
NaH2PO4× 1 H2O (Merck, Darmstadt, Germany). The solution was
adjusted to a pH of 7.4 and stored at 4 ◦C.
Stock solutions of carbachol (10−1 M)  and oxybutynin (10−2 M)
were stored at −80 ◦C, dilutions with Krebs solution were freshly
prepared for each experiment.
124  mM KCl-Krebs solution contained (in mmol/l): 124 KCl
(Haenseler AG, Herisau, Switzerland), 1.5 CaCl2 (Merck, Darm-
stadt, Germany), 1.2 MgCl2× 6 H2O (Merck, Darmstadt, Germany),
15.0 NaHCO3 (Merck, Darmstadt, Germany), 1.2 NaH2PO4× 1 H2O
(Merck, Darmstadt, Germany), 11.0 Glucose (Sigma–Aldrich, Stein-
heim, Germany). The solution was  adjusted to a pH 7.4 and stored
at 4 ◦C. Ecotainer® Aqua (B. Braun, Sempach, Switzerland) was used
as the solvent for all solutions.
Porcine urinary bladder
Due  to similar density and pharmacological characteristics of
the muscarinic receptors in porcine and human bladder tissue
(Sellers and McKay 2007), the consistency of electrical properties of
detrusor smooth muscle from the porcine and human urinary blad-
der (Hashitani and Brading 2003), and good accessibility of porcine
bladders, we  decided to carry out the contractility experiments
on porcine detrusor strips. Empty porcine urinary bladders were
obtained from a local slaughterhouse where they were immediately
immersed in cool Krebs solution for the transport. The mucosal lay-
ers were removed, and detrusor strips (2 × 1 × 5 mm)  were cut in
a longitudinal direction from the bladder wall. Isometric tension
recordings were performed within 7 h.
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Functional experiments
Porcine  detrusor strips were mounted in a 6 ml  tissue bath
chamber (610M, Muscle Strip Myograph System, DMT, Denmark,
supplied by ADInstruments GmbH, Spechbach, Germany) filled
with Krebs solution, serated with 95% O2 and 5% CO2 at 37 ◦C.
The tissue was fixed between two clamps. Contractile responses
were recorded and digitized using AD Instruments PowerLab force
transducer model 4/30 in connection with LabChartPro 7.0 software
(ADInstruments, Sydney, Australia). An initial equilibration period
of 0.5 g for a minimum of 30 min  was allowed before starting the
experiments.
Inhibitory effect measurements: Electrical field stimulation
(EFS) was applied through a Grass S48 electrical stimulator (Astro-
Med inc., W.  Warwick, RI, USA) and two electrodes placed on each
side of the strips. Contractions were induced by squared twin pulses
of 40 V, 32 Hz, with a duration of 2 ms,  given for 5 s with an inter-
val of 3 min. The first stimulation after the equilibration period
was performed to get the maximum amplitude of the contraction;
thereby the mean of 3 similar peaks was used. Subsequently BPJ
(0.1, 0.5, 1, 2.5, 5 and 10%) was added cumulatively followed by elec-
trical stimulation after each BPJ application. The incubation time
for each BPJ concentration was 5 min  and the next higher concen-
tration was added after three similar amplitudes. One strip per run
without addition of any substance was used as control. Oxybutynin
(10−5 to 10−3 M)  was used as a reference substance.
Relaxant effect measurements: The strips were stimulated with
50 !M carbachol to obtain a constant level of tension. Then BPJ
was added with cumulative concentrations (0.1, 0.5, 1, 2.5, 5 and
10%). In the following washout phase, Krebs solution was changed
4 times until the strips achieved baseline tension. Carbachol 50 !M
was added again to check the contractility of the strips after the
treatment with BPJ. Oxybutynin (10−7 to 10−5 M)  was  used as a
reference substance. One strip of every run was  used as a time-
matched control without addition of any substance.
Data analysis and statistics
In the EFS inhibition experiments, the mean of 3 amplitudes
before addition of BPJ or oxybutynin was defined as 100% con-
traction. Values after addition of BPJ, oxybutynin or the control,
respectively, were expressed as the percentage of the 100% value;
for each concentration the mean of 3 amplitudes was  used. In
relaxation experiments, the difference between the mean of ampli-
tudes before the addition of carbachol (=baseline) and the mean
immediately after the addition of carbachol was defined as 100%
contraction. The relaxant effect after addition of each concentra-
tion of BPJ or oxybutynin was expressed as a percentage of the 100%
value. Results of the experiments are expressed as mean ± standard
error of the mean (SEM). Statistical significance of differences
between BPJ or oxybutynin and the time-matched controls were
determined using an unpaired Student’s two-tailed t-test (Excel,
Microsoft Office 2007) with a probability level of p < 0.05 being
considered significant.
Results
A  total of 32 bladders were used for the experiments.
Inhibition of electrically induced contractions
BPJ (n = 7) reduced the muscle tension to 87.1 ± 5.4%, 53.4 ± 8.7%,
32.5 ± 10.2% and 33.2 ± 16.8% at concentrations of 1, 2.5, 5 and 10%
BPJ, respectively. Compared to the time matched control group
(n = 12), BPJ showed a significant inhibition at 1, 2.5, 5 and 10% BPJ
(p < 0.05, p < 0.01, p < 0.001); the maximum inhibitory effect was
74.6 ± 10.2% at the concentration of 5% (p < 0.001) (Fig. 1A).
Oxybutynin (n = 6) reduced the muscle tension to 53.1 ± 9.4%,
28.9 ± 6.3%, 19.4 ± 5.1%, 11.0 ± 4.0%, 5.9 ± 2.4% and 4.0 ± 1.4% at
concentrations between 10−5 and 10−3 M,  respectively. Compared
to the time matched control group (n = 12) it showed a significant
inhibition at 10−5 to 10−3 M (p < 0.0001); the maximum inhibitory
effect was 96.0 ± 1.4% at a concentration of 10−3 M (p < 0.0001)
(Fig. 1B).
Relaxation of carbachol induced contractions
BPJ (n = 9) and the anticholinergic reference substance oxybu-
tynin (n = 6) produced a concentration-dependent relaxation of the
carbachol pre-contracted detrusor strips. BPJ was  able to reduce
the tension to 53.6 ± 3.1% and 48.3 ± 3.7%. Compared to the time
matched control group (n = 11), BPJ showed a significant relaxation
at 5 and 10% (p < 0.05); the maximum relaxant effect was 18.7 ± 3.7
at 10% BPJ (Fig. 2A).
Oxybutynin  was  able to reduce the tension to 52.4 ± 5.6%,
30.3 ± 5.3%, 21.6 ± 3.9%, 15.1 ± 3.0%, and 10.4 ± 3.2% at concen-
trations of 10−6.5 M,  10−6 M,  10−5.75 M,  10−5.5 M and 10−5 M,
respectively.  Compared to the time matched control (n = 11)
oxybutynin showed a significant relaxation (p < 0.001) at all con-
centrations except 10−7 M;  it led to a maximum relaxant effect of
56.7 ± 3.2% at 10−5 M (Fig. 2B).
Discussion
Despite the high prevalence and the considerable impact on
quality of life, pharmacological treatment options for patients
suffering from OAB are still limited. Herbal drugs are generally con-
sidered to be as effective as synthetic products. The identification
of a nature-derived drug with a good activity and tolerability would
be a relief for both patients suffering from OAB and their attending
physician.
B. pinnatum is widely used in traditional medicine in different
parts of the world (Kamboj and Saluja 2009). Its muscle relaxant
activity to human myometrium in vitro and in vivo has been shown
before (Plangger et al. 2006; Wächter et al. 2011; Gwehenberger
et al. 2004). Therefore, we  investigated the inhibitory and relaxant
effect of BPJ on the contractions of isolated porcine detrusor muscle
strips induced by electrical and chemical stimulation.
This experiment shows that BPJ in concentrations of 1–10% leads
to an inhibition of electrically induced contractions. The inhibition
was more pronounced for oxybutynin than for BPJ at all concentra-
tions investigated (0.01–1 !M vs. 1–10%, respectively). However, it
is difficult to compare the results of a press juice with a chemically
defined substance since the compounds responsible for the activity
of BPJ and their concentration are not completely characterised
yet. Both substances led to a concentration-dependent relaxation
of carbachol-induced contractions. However, the inhibitory effect
on the contractility of porcine detrusor muscle was more distin-
guished than the relaxant. One reason for the divergent results
in these two  experiments could be that the signalling pathways
leading to contraction and relaxation of the detrusor smooth
muscle differ. The stimulation of muscarinic receptors on the
detrusor by acetylcholine, which is physiologically released from
activated cholinergic nerves, is the main mechanism of bladder
contraction (Chapple et al. 2008). This stimulation is known to
be competitively inhibited by oxybutynin, our comparative study
drug for relaxation and inhibition measurements. The M3-receptor
subtype predominantly mediates bladder contraction despite the
large majority of the M2-receptor subtype expressed in the bladder
mucosa (Chapple et al. 2008). The role of the M2-receptor subtype
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Fig. 1. Inhibitory effect of B. pinnatum leaf press juice (A) and oxybutynin (B), respectively, on electrically induced contractions of porcine detrusor muscle. 100% of the
contraction was  defined as mean of the 3 amplitudes before addition of the drug in increasing concentrations. The strips were stimulated after each addition of the drug.
Mean values ± SEM of the treated group and of the time-matched control group are shown. Appropriate values were compared to those of the control group by the unpaired
Student’s two tailed t-test. *p < 0.05, **p < 0.01 and ***p < 0.001.
is not yet clarified. The M2-receptor may  play an indirect role
in mediating bladder contractions by enhancing the contractile
response to M3-activation (Chapple 2000). However, an explana-
tion for our results is that the strong inhibitory effect of BPJ may  be
triggered by the inhibition of M3-receptors, whereas the relaxant
effect is mediated by the stimulation of the M2-receptor subtype.
Since the expression of muscarinic receptors and the electrical
properties of detrusor smooth muscle from the porcine and
human urinary bladder are very similar (Sellers and McKay 2007),
B. pinnatum may  have a comparable effect on human detrusor.
Oxybutynin was shown to effectively block carbachol-induced
contractions in numerous investigations. Its affinity for M1- and
M3-receptors exceeds that of M2-subtypes (Andersson 2011).
Besides cholinergic control of detrusor contractions, other mecha-
nisms of actions have been discussed. They include, among others,
the inhibition of the influx of extracellular calcium into detrusor
muscle cells by L-type Ca2+-channel blockers or K+-channel openers
(Sacco et al. 2008).
Taking  into account the favourable side effect profile of BPJ
in previous studies (Plangger et al. 2006), a muscarinic indepen-
dent or balanced pathway might be suggested. Since BPJ contains
a multitude of different compounds which are poorly studied,
we cannot conclude on their potential affinity to muscarinic or
adrenergic receptors, Ca2+ or K+ channels or other targets. We
recently showed that B. pinnatum inhibits the oxytocin-induced
increase of intracellular calcium concentration in human myome-
trial cells in a dose-dependent, but extracellular Ca2+-independent,
manner. At the same time B. pinnatum delays (but not fully pre-
vents) the depolarization-induced increase in intracellular Ca2+ in
cells known to express L-type Ca2+-channels (Simões-Wüst et al.
2010). Whether a comparable delay can explain the now observed
inhibitory effect on the contraction of detrusor smooth muscle cells
deserves further investigation. In addition, radioligand displacing
studies would possibly offer a suitable method to investigate the
receptor - or ion channel-binding properties of BPJ constituents in
detrusor smooth muscle cells.
Furthermore, we  recently showed that a flavonoid-containing
fraction from BPJ was pharmacologically active and produced relax-
ation of the myometrium (Gwehenberger et al. 2004).
Other plants have been previously investigated for their in vitro
inhibitory properties on detrusor contractility, such as Ylang Ylang
(Cananga odorata) (Kim et al. 2003), St. John’s Wort (Hypericum
perforatum) (Capasso et al. 2004), European gold rod (Solidago
virgaurea) (Borchert et al. 2004) and sweet sumach bark (Rhus aro-
matica) (Borchert et al. 2004). However, none of these herbal drugs
have been further developed towards a novel treatment option for
OAB, and the need for effective and well tolerated phytopharma-
ceuticals remains. Since B. pinnatum has been shown to effectively
inhibit uterine contractions in vitro (Gwehenberger et al. 2004), and
to produce few and only moderate side effects in vivo (Plangger et al.
Fig. 2. Relaxant effect of B. pinnatum leaf press juice (A) and oxybutynin (B), respectively on carbachol-induced contractions of porcine detrusor muscle. Tension of 100%
represents the difference between the level before and after addition of 50 !M carbachol. The drug in each concentration was cumulatively added to the strips. Mean
values ± SEM of the treated group and of the time-matched control group are shown. Appropriate values were compared to those of the control group by the unpaired
Student’s two tailed t-test. *p < 0.05 and ***p < 0.001.
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2006) this plant appears highly promising as a future treatment
option for OAB disorders. Identification of the pharmacologically
active compounds in the extract, and an investigation of their
mechanism of action are planned as next steps in the develop-
ment of Bryophyllum pinnatum towards a potential new treatment
of overactive bladder.
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This publication demonstrated the effect of the leaf press juice as well as of the flavonoid, 
bufadienolide, and polar fractions of B. pinnatum on porcine detrusor contractility in vitro. The 
leaf press juice was able to inhibit electrically stimulated detrusor concentrations in an organ 
bath. The flavonoid fraction (1 mg/mL) produced a 78.7% maximum inhibition of detrusor 
contractility. Muscle strips treated with the bufadienolide fraction demonstrated no inhibitory 
effects on detrusor contractility. The polar fraction demonstrated an unexpected inhibitory 
effect; however, this effect may be explained by a lower pH in the organ bath chamber 
caused by the presence of L-malic acid. Flavonoids are hypothesized to be responsible for 




The preparation of the flavonoid, bufadienolide, and polar fractions (liquid-liquid extraction 
and Diaion HP-20 CC), identification of the fractions constituents, the method development, 
in vitro experiment performance, the pH measurements, writing of the manuscript, and 
preparation of the figures (except for Fig. S3, S4) and tables were my contributions to this 
publication. 
 Karin Fürer 
 118 
Inhibition of porcine detrusor contractility by the flavonoid fraction of Bryophyllum pinnatum – 
a potential phytotherapeutic drug for the treatment of the overactive bladder syndrome 
 
K. Fürera,b§, D. Eberlic§, C. Betschartd, R. Brenneisene, M. De Mierib, M. Hamburgerb, M. Mennet-von 




a Department of Obstetrics, University Hospital Zurich, CH-8091 Zurich, Switzerland  
b Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, 
CH-4056 Basel, Switzerland 
c Urology Clinic, University Hospital Zurich, CH-8091 Zurich, Switzerland 
d Department of Gynaecology, University Hospital Zurich, CH-8091 Zurich, Switzerland 
e Department of Clinical Research, University of Bern, CH-3010 Bern, Switzerland 
f Weleda AG, CH-4144 Arlesheim, Switzerland 
g Research Department, Paracelsus Hospital Richterswil, CH-8805 Richterswil, Switzerland 
 
Correspondence 
*Prof. Dr. pharm. Ursula von Mandach, Department of Obstetrics, University Hospital Zurich, 
Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland. 
Email: ursula.vonmandach@usz.ch 
Phone: +41 44 255 51 36 Fax: +41 44 255 44 30 
§both authors contributed equally to this work 
 
Keywords 




APCI: Atmospheric-pressure chemical ionization 
BPJ: Bryophyllum pinnatum leaf press juice 
[Ca2+]i: Intracellular free calcium concentration 
CC: Column chromatography 
EFS: Electrical field stimulation 
ESI: Electrospray ionization 
HPLC: High-performance liquid chromatography 
OAB: Overactive bladder syndrome 




6&<=! A@&! 35'! @?'&(03/?'! *.(66'&! 4K86&@;')! (86! 3@! 05(&(03'&/4'! 35'! A&(03/@8! &'4J@84/*.'! A@&! 35'!
/85/*/3/@8!@A!6'3&<4@&!0@83&(03/./3K#!
5(,&'634! $&(03/@84!Q'&'! J&'J(&'6! A&@;! 35'!9'B:! '\3&(03! @A) -7) *+$$",01! (86! A<&35'&! (8(.K4'6! *K!







T#Xg! fP! ;=i;dh! Q5/.'! 35'! *<A(6/'8@./6'! A&(03/@8! 5(6! 8@! /85/*/3@&K! 'AA'03! /8! 35'! /8?'43/=(3'6!
0@80'83&(3/@84#!e5'!J@.(&!A&(03/@8!45@Q'6!(!&'6<03/@8!@A!35'!0@83&(03/./3K!/8!(!J:>6'J'86'83!A(45/@8#!
















*'8'A/3#! :@Q'?'&)! ;(8K! J(3/'834! 4<AA'&! A&@;! (83/05@./8'&=/0! 4/6'! 'AA'034)! .(0^! @A! 'AA/0(0K)! @&!
<8A<.A/..'6! 3&'(3;'83! '\J'03(3/@84#! HJ! 3@! XNg! @A! 35'! J(3/'834! A(/.! 3@! &'4J@86! (6']<(3'.K)! @&! 35'/&!
'\J'03(3/@84!Q'&'!3@@!5/=5!fl''8*@'&!(86!2@405)!XNPSh#!
E4! (! 8'Q! 35'&(J'<3/0! (JJ&@(05! ȕW>(6&'8@0'J3@&! (=@8/434! 5(?'! *''8! /8?'43/=(3'6#! 9/&(*'=&@8! Q(4!
&'0'83.K! /83&@6<0'6! (4! (! 3&'(3;'83! @A! BE2#! E! ;<.3/0'83'&! &(86@;/R'6! 6@<*.'>*./86! 43<6K! 45@Q'6!
=@@6!'AA/0(0K!(86!3@.'&(*/./3K!0@;J(&'6!3@!J.(0'*@!f"5<..(&!'3!(.#)!XNPWm!15(JJ.'!'3!(.#)!XNPWh#!
_A! 0@84'&?(3/?'! 3&'(3;'83! A(/.4)! 4<&=/0(.! /83'&?'83/@84! ./^'! *@3<./8<;! 3@\/8! /8a'03/@8)! 4(0&(.! 8'&?'!
43/;<.(3/@8)!@&!6'3&<4@&!;K'03@;K!(&'!&'0@;;'86'6!(4!A<&35'&!@J3/@84!fe@@R4>:@*4@8)!XNPNh#!
V/?'8! 35'! 6&(Q*(0^4! @A! 35'! (*@?'>;'83/@8'6! (JJ&@(05'4)! (.3'&8(3/?'! J5(&;(0@.@=/0(.! 3&'(3;'83!
@J3/@84! Q@<.6! *'! @A! ?(.<'! A@&! J(3/'834! 4<AA'&/8=! A&@;! BE2#! C&'?/@<4! &'4'(&05! /86/0(3'6! 35(3!
-./'*&/##01)*+$$",01!0@<.6!*'!4<05!(!8'Q!35'&(J'<3/0!(JJ&@(05#!
-./'*&/##01)*+$$",01! fd(;#h!B^'8! f4K8#!!"#"$%&'()*+$$","!C'&4#)!-./'*&/##01)%"#/%+$01!D(./4*#)!
1&(44<.(0'('h! /4! (! 4<00<.'83! J'&'88/(.! J.(83! 8(3/?'! 3@! 9(6(=(40(&#! e5'! .'(?'4! 5(?'! *''8! <4'6! /8!
3&(6/3/@8(.)! 8(3/?')! (86! (835&@J@4@J5/0(.!;'6/0/8'! f"(;*@a! (86! D(.<a()! XNNOm!,(';4! '3! (.#)! POMXh#!
D/80'! POkN)!-7) *+$$",01! /4! <4'6! (4! (! 3@0@.K3/0! (='83! 3@! J&'?'83! J&';(3<&'! .(*@<&! f:(44(<'&! '3! (.#)!
POMTh#! d'(A! J&'44! a</0'! (86! (! A.(?@8@/6! A&(03/@8! @A!-7) *+$$",01!Q'&'! 45@Q8! 3@! /86<0'!;K@;'3&/(.!
&'.(\(3/@8!+$):+,.'!fGn053'&!'3!(.#)!XNPPh#!
D/;/.(&!'AA'034!0@<.6!*'!6';@843&(3'6!@8!*.(66'&!6'3&<4@&!;<40.'!Q5'&'!-7)*+$$",01).'(A!J&'44!a</0'!




2(4'6! @8! 35'4'! A/86/8=4)! Q'! A<&35'&! /8?'43/=(3'6! 35'! 'AA'03! @A! -7) *+$$",01! @8! J@&0/8'! 6'3&<4@&!
0@83&(03/./3K#!:'&*(.!'\3&(034!0@83(/8!(!;<.3/3<6'!@A!6/AA'&'83!J5K3@05';/0(.4#!-7)*+$$",01!/4!^8@Q8!3@!
















-7)*+$$",01! .'(A!J&'44! a</0'! f2C`hY!d'(?'4!Q'&'!5(&?'43'6! /8!9(&05!XNPN! A&@;!J.(834! 0<.3/?(3'6! /8!




-7) *+$$",01) .'(?'4Y! d'(?'4! Q'&'! 5(&?'43'6! /8! E<=<43! XNPN! A&@;! J.(834! 0<.3/?(3'6! /8! D05Qn*/405!








2&<^'&! -4]</&'! WNNN! J.<4! ;(44! 4J'03&@;'3'&! ']</JJ'6! Q/35! -D_! @&! EC1_! 4@<&0'#! 9D! 6(3(! Q'&'!
&'0@&6'6!/8!J@4/3/?'!/@8!;@6'#!D'J(&(3/@84!Q'&'!(05/'?'6!@8!(!D<8$/&'e9!1PM!0@.<;8!fW#T!ȝ;)!W!\!PTN!
;;)! G(3'&4h! ']</JJ'6! Q/35! (! =<(&6! 0@.<;8! fW! \! PN! ;;h#! e5'! ;@*/.'! J5(4'! 0@84/43'6! @A! N#Pg!
(]<'@<4!A@&;/0!(0/6!fEh!(86!9'1o!f2h)!(86!(!./8'(&!=&(6/'83!@A!T>PNNg!2!/8!WN!;/8!Q/35!(!A.@Q!&(3'!
@A!N#T!;di;/8!Q(4!(JJ./'6#!
C&'J(&(3/?'! A&(03/@8(3/@8! @A! '\3&(03! @8! ,/(/@8! :C>XN! fXTN! ȝ;)! D<J'.0@h! Q(4! (05/'?'6! /8! (! =.(44!
0@.<;8!fkN!\!kNN!;;h#!







7'A'&'80'! 4<*43(80'4! <4'6! A@&! 0@;J@<86! /6'83/A/0(3/@8! Q'&'! J&'?/@<4.K! /4@.(3'6! A&@;! 35'! 9'B:!




$&@R'8! .'(?'4! @A! -7) *+$$",01! Q'&'! .K@J5/./4'6)! (86! J<.?'&/4'6! /8! (! ;@&3(&#! e5'! J@Q6'&'6! .'(?'4!
fPNUS#k!=h!Q'&'!'\3&(03'6!Q/35!9'B:!fPN!dh#!e5'!4<4J'84/@8!Q(4!43/&&'6!X5!(3!&#3#!(86!4<*4']<'83.K!















A phenolic acid derivative and nine flavonoid glycosides were identified in the flavonoid fraction by 
ESIMS analysis (Fig. 1): syringic acid ȕ-D-glucopyranosyl ester (1), quercetin 3-O-Į-L-
arabinopyranosyl-(1 o 2)-Į-L-rhamnopyranoside 7-O-ȕ-D-glucopyranoside (2), myricetin 3-O-Į-L-
arabinopyranosyl-(1 o 2)-Į-L-rhamnopyranoside (3), myricitrin (4), quercetin 3-O-Į-L-
arabinopyranosyl-(1 o 2)-Į-L-rhamnopyranoside (5), diosmine (6), quercitrin (7), kaempferol 3-O-Į-
L-arabinopyranosyl-(1 o 2)-Į-L-rhamnopyranoside (8), kaempferol 3-O-ȕ-D-xylopyranosyl-(1 o 2)-
Į-L-rhamnopyranoside (9), and acacetin 7-O-Į-L-rhamnopyranosyl-(1 o 6)-ȕ-D-glucopyranoside 
(10) (Fig. 2). 
APCIMS analysis revealed four bufadienolides, which were unambiguously identified in the 
bufadienolide fraction (detailed results are provided as supporting information): bersaldegenin-1-
acetate (11), bryophyllin A (12), bersaldegenin-3-acetate (13), and bersaldegenin-1,3,5-orthoacetate 
(14) (Fig. 3). 
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Constituents of the polar fraction could not be identified by ESIMS and APCIMS. Therefore, 1H NMR 
analysis of the polar fraction was performed to identify its constituents. Based on the 1H NMR 
spectrum, the polar fraction contains mainly L-malic acid as well as different sugars (detailed results 
are provided as supporting information). 
 
Porcine bladder muscle strips  
For in vitro contractility experiments the Krebs solution (pH 7.4) containing (in mmol/L) 119.0 NaCl 
(AppliChem, Darmstadt, Germany), 15.0 NaHCO3 (Sigma-Aldrich, Steinheim, Germany), 11.0 
Glucose (Sigma-Aldrich, Steinheim, Germany), 4.6 KCl (Zurich canton pharmacy, Zurich, 
Switzerland), 1.5 CaCl2 (Dr. Bender & Dr. Hobein AG, Zurich, Switzerland) 1.2 MgCl2 x 6 H2O 
(AppliChem, Darmstadt, Germany), 1.2 NaH2PO4 x H2O (Merck, Darmstadt, Germany) was used 
(Badawi et al., 2006). 
Oxybutynin chloride (Fig. 4), L-malic acid, D-malic acid and succinic acid were purchased from 
Sigma-Aldrich. 
Porcine urinary bladders were obtained from the slaughterhouse in Zurich. They were from 5 months 
old female pigs weighing around 100 kg. Immediately after slaughtering, bladders were kept in Krebs 
solution. All experiments were done within 9 hours after removal of bladders. 
Bladders were emptied before cutting off the dome and trigone. The urothelium was carefully 
removed from the detrusor. After, the serosa was removed and longitudinal muscle strips (5 x 2 x 1 
mm3, 25 - 40 mg) were prepared. Eight muscle strips were deposited in Krebs solution (on ice) until 
use.  
 
Organ bath measurements 
The experiments were performed with a DMT 610M Multi Chamber Myograph connected to an 
ADInstruments PowerLab 4/30 signal transducer and to a Grass S48 Electrical field stimulator. In the 
organ bath chamber (Krebs solution aired with 5% CO2 and 95% O2, 6 mL, 37°C) the strips were fixed 
between two jaws, which were connected either to a force transducer or a micropositioner. 
The electrical field stimulation (EFS) was performed with squared twin pulses with duration of 2 ms 
and an interval of 3 min. The muscle strips were stimulated for 5 seconds with a constant voltage and 
frequency (40 V, 32 Hz) and the contraction force recorded. 
After attaching the muscle strips, an equilibrium phase with 10 mN was applied. The stretching of the 
muscle strips was repeated after 5 and 10 min. Krebs solution was exchanged every 10 min. After 30 
min of equilibration, the baseline contraction force of each strip was set to zero. Before application of 
test solutions, the muscle strips were stimulated 7 times each 3 min by EFS to determine the maximum 
contraction of each strip. 
BPJ, fractions, oxybutynin, or control solution (Krebs solution or DMSO (0.5%)) were added in the 
corresponding concentration to the organ bath chamber. The following concentrations were tested: 
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Legends of Figures 
 
Fig. 1 HPLC-PDA-ESI-MS of the flavonoid fraction. Top: UV trace (200-700 nm). Bottom: ESIMS 
base peak chromatogram (positive ion mode, m/z 150-1500). SunfireTM C18 column, A: 0.1% aqueous 
formic acid and B: MeCN, 5-100% B in A in 30 min, 0.5 mL/min. Numbers refer to the isolated 

















Fig. 5 Effect of B. pinnatum leaf press juice (2.5 - 10%) on porcine detrusor contractility. The 
maximum contractility before treatment was set as 100%. Krebs solution was used as control. Mean 
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